Chemical composition of specimens in wt.%.
\r\n\t
",isbn:"978-1-83969-347-2",printIsbn:"978-1-83969-346-5",pdfIsbn:"978-1-83969-348-9",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!0,hash:"4fc73beb0e4416a20cc70c8163fe436f",bookSignature:"Dr. Pinar Erkekoglu",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/9836.jpg",keywords:"KRAS Gene, Oncogene, Tumor Suppressor Gene, Mutation, Cancer, Microtubule-Associated Protein (MAP), GTPase, Pathological Conditions, Epidermal Nevus, Noonan Syndrome, Costello Syndrome, Environmental Chemicals",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"November 17th 2020",dateEndSecondStepPublish:"December 15th 2020",dateEndThirdStepPublish:"February 13th 2021",dateEndFourthStepPublish:"May 4th 2021",dateEndFifthStepPublish:"July 3rd 2021",remainingDaysToSecondStep:"a month",secondStepPassed:!0,currentStepOfPublishingProcess:3,editedByType:null,kuFlag:!1,biosketch:"A pioneering researcher in toxicology, vaccinology, cosmetics, and Board Member of Turkish Pharmacists Association Pharmacy Academia and Board Member of Hacettepe Vaccine Institute. Published more than 150 scientific papers in international/national journals. Associate editor of the Turkish Journal of Pharmaceutical Sciences.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"109978",title:"Prof.",name:"Pinar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pinar Erkekoglu",profilePictureURL:"https://mts.intechopen.com/storage/users/109978/images/system/109978.JPG",biography:"Pınar Erkekoglu was born in Ankara, Turkey. She graduated with a BS from Hacettepe University Faculty of Pharmacy. Later, she received an MSci and Ph.D. in Toxicology. She completed a part of her Ph.D. studies in Grenoble, France, at Universite Joseph Fourier and CEA/INAC/LAN after receiving a full scholarship from both the Erasmus Scholarship Program and CEA. She worked as a post-doc and a visiting associate in the Biological Engineering Department at Massachusetts Institute of Technology. She is currently working as a full professor at Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology. Her main study interests are clinical and medical aspects of toxicology, endocrine-disrupting chemicals, and oxidative stress. She has published more than 150 papers in national and international journals. Dr. Erkekoglu has been a European Registered Toxicologist (ERT) since 2014.",institutionString:"Hacettepe University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"4",totalChapterViews:"0",totalEditedBooks:"4",institution:{name:"Hacettepe University",institutionURL:null,country:{name:"Turkey"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"6",title:"Biochemistry, Genetics and Molecular Biology",slug:"biochemistry-genetics-and-molecular-biology"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"301331",firstName:"Mia",lastName:"Vulovic",middleName:null,title:"Mrs.",imageUrl:"https://mts.intechopen.com/storage/users/301331/images/8498_n.jpg",email:"mia.v@intechopen.com",biography:"As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"5176",title:"Nutritional Deficiency",subtitle:null,isOpenForSubmission:!1,hash:"a2e20dabc8ed6fbaef3686be8c6fce99",slug:"nutritional-deficiency",bookSignature:"Pınar Erkekoglu and Belma Kocer-Gumusel",coverURL:"https://cdn.intechopen.com/books/images_new/5176.jpg",editedByType:"Edited by",editors:[{id:"109978",title:"Prof.",name:"Pinar",surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pinar Erkekoglu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5836",title:"Bisphenol A",subtitle:"Exposure and Health Risks",isOpenForSubmission:!1,hash:"446599b9e5cf929537d445edc546c449",slug:"bisphenol-a-exposure-and-health-risks",bookSignature:"Pinar Erkekoglu and Belma Kocer-Gumusel",coverURL:"https://cdn.intechopen.com/books/images_new/5836.jpg",editedByType:"Edited by",editors:[{id:"109978",title:"Prof.",name:"Pinar",surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pinar Erkekoglu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7281",title:"Oncogenes and Carcinogenesis",subtitle:null,isOpenForSubmission:!1,hash:"728df4ace35f652725e5b94da45d0c4d",slug:"oncogenes-and-carcinogenesis",bookSignature:"Pinar Erkekoglu",coverURL:"https://cdn.intechopen.com/books/images_new/7281.jpg",editedByType:"Edited by",editors:[{id:"109978",title:"Prof.",name:"Pinar",surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pinar Erkekoglu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6486",title:"Glutathione in Health and Disease",subtitle:null,isOpenForSubmission:!1,hash:"23fb1f2e0cea5cf004d57bc8c0d46ce4",slug:"glutathione-in-health-and-disease",bookSignature:"Pinar Erkekoglu and Belma Kocer-Gumusel",coverURL:"https://cdn.intechopen.com/books/images_new/6486.jpg",editedByType:"Edited by",editors:[{id:"109978",title:"Prof.",name:"Pinar",surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pinar Erkekoglu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6694",title:"New Trends in Ion Exchange Studies",subtitle:null,isOpenForSubmission:!1,hash:"3de8c8b090fd8faa7c11ec5b387c486a",slug:"new-trends-in-ion-exchange-studies",bookSignature:"Selcan Karakuş",coverURL:"https://cdn.intechopen.com/books/images_new/6694.jpg",editedByType:"Edited by",editors:[{id:"206110",title:"Dr.",name:"Selcan",surname:"Karakuş",slug:"selcan-karakus",fullName:"Selcan Karakuş"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"68771",title:"Microstructure and Property Co-relation of 4% Carbon Fe-C Alloy System",doi:"10.5772/intechopen.86203",slug:"microstructure-and-property-co-relation-of-4-carbon-fe-c-alloy-system",body:'\nThe iron-carbon (Fe-C) system is a binary alloy system that comprises of 6.67% (max.) of carbon in iron, which is further classified into two alloys i.e., steel comprises of maximum 2% of C and cast iron having carbon that ranges from 2 to 6.67%. The cast iron is further classified into white cast iron and gray cast iron depending on the microstructure so obtained after the casting process. However the desired morphology to be obtained at room temperature can only be modified at the time of inoculation during the melting process by adding appropriate amount of alloying elements. Steel is the most preferable candidate for structural application as it possesses a good combination of strength, hardness, ductility, and impact toughness, whereas cast iron finds its application where the system is subjected to vibration such as base for heavy machinery installation. In structural application cast iron does not sit suitably due to its brittle nature that allows rapid fracture growth, having a high strength but low ductility and low impact toughness. The reason for such behavior is the nature of graphite in the final microstructure which remains in the form of flakes with sharp edges that result in stress concentration sites upon loading and ultimately quicker crack propagation.
\nSpheroidal graphite cast iron (SGCI)/ductile cast iron (DCI) as the name suggests, has graphite in spherical form embedded in the matrix. The spherical shape is achieved by the addition of magnesium (Mg) and/or cerium (Ce) as inoculants, to the gray cast iron melt during the casting process. The graphite spheroids do not interfere with matrix continuity and eliminate the stress concentration effect that generates due to the presence of flaky graphite in case of gray cast iron, leading to improved ductility and impact toughness without affecting the strength and hardness. In addition, to these advantages, it possesses ease of castability, machinability and less cost of production. Because of these enhanced properties over the other cast irons, during the last five decades, the production and commercialization of SGCI have grown immensely. The versatility of SGCI in strength, toughness, tribological behavior and resistance to corrosion made it the preferable candidate for structural, automotive, agricultural and many more application including nuclear industry as well. Though in as-received form via melting and casting, it discloses desired property combination for the particular application, the properties can further be improved by employing suitable heat treatment techniques. The austempering heat treated ductile iron (refereed as ADI) shows excellent combination of high strength and toughness [1, 2] along with better wear resistance [3, 4], excellent fatigue strength [5, 6] as well as fracture toughness [7, 8]. Application of suitable heat treatment process leads to transformation of as-cast ferritic or ferritic/pearlitic matrix into fully pearlitic, martensitic, and bainitic resulting variation in the properties. Among all the heat treatment processes employed the austempering treatment resulting in bainitic matrix is the most favorable member due to its strength, impact toughness, tribological behavior as well as fatigue and fracture toughness [9, 10, 11, 12, 13]. Tribological properties of austempered ductile iron (ADI) is observed to be in direct relationship with the austempering temperature and time. The consequences being increased hardness during the wear attributed to the fact that, the bainitic ferrite in the matrix undergoes strain hardening as it is less prone to thermal instability as compared to martensite [14]. On the other hand the tempering treatment with Boron alloyed DI reported to result in increased wear resistance; however, it decreases with increased boriding time [15]. Not only the matrix microstructure and alloying element is responsible for the wear behavior, but also as reported by Sugishita and Fujiyoshi [16]. Zimba et al. [17] the graphite characteristics viz. nodule size and distribution in the matrix has significant effect on the wear properties as well.
\nTo achieve desired properties for a particular application, control over matrix structure and morphological aspects is necessary, and that can be achieved by controlling processing parameters and the addition of alloying elements. The addition of alloying elements influences the mechanical properties by changing the cast matrix microstructure from ferritic to pearlitic, ferritic/pearlitic and/or austenitic depending upon the alloy composition. If the processing parameters such as tapping temperature and cooling rate are kept constant, the final matrix bends toward the matrix influencing element. Incorporation of Ni from 12 to 38% (max.), a highly ductile material of austenitic SGCI is obtained. On the other hand, a higher Si amount results in ferritic matrix and that of Cu and Mn lead to the formation of harder pearlitic matrix. A proper control of ferrite and pearlite influencing elements results in a mixed ferritic/pearlitic structure having properties intermediate between ferritic and pearlitic grades of SGCI.
\nSilicon is the most vital element in the production of SGCI and influences the solidification process in conjunction with Carbon. An increase of 1% Si content shifts the eutectic composition toward the left (approximately 0.30% of carbon), resulting in low solidification temperature. With increasing Si content the eutectoid carbon content is lowered, and hence transformation occurs over a broadening range. Figure 1(a) depicts the inverse relationship of carbide content in the matrix with silicon content, and as disclosed with increased Si content there is a decrease in the carbide formation. Silicon is a graphitizer and ferrite promoter, hence reduces the strength properties of ferritic ductile iron, which if needed, further can be improved by the addition of desired amount of nickel. Increased silicon content increases the carbon equivalent (%CE), hence prevents the precipitation of carbides and allows the formation of more free form of carbon leading to increased nodule count (Figure 1(b)) and decreased hardness and UTS [18, 19, 20]. On the other hand, for austenitic grades increase in Si content increases the tensile strength and 0.2% yield strength [18]. The substantial influence of silicon on the ductile-brittle transition temperature of ferritic ductile iron is shown in Figure 2 [21]. From Figure 1, it is clearly understood that to achieve optimum low-temperature toughness, the amount of Si should be maintained as low as possible. Fully ferritic carbide free ductile iron production needs high purity charge materials, proper holding and casting practice and highly effective inoculation for maximum nodule count. Higher amount of silicon leads to a reduction in low impact toughness, increased DBTT and decreased thermal conductivity. Si is held below 2.2% when producing the ferritic grades and between 2.5 and 2.8% when producing pearlitic grades [19, 20].
\nVariation of carbide percentage (a) and nodule count (b) in ductile cast iron with silicon.
Influence of silicon content on the v-notched Charpy energy of ferritic ductile iron [22].
Manganese is a very strong carbide stabilizer at eutectoid graphitization and increases the amount of combined carbon. Excess Mn has little effect on solidification and only weakly retards primary graphitization. The presence of a correct amount of Mn forms manganese sulfide and reduces the proportion of combined carbon by removing the effect of sulfur [23]. Being a mild perlite promoter it results in increased hardness and proof stress but to a smaller extent. Manganese is added to the liquid melt to a limited amount as because it prevents the initiation of eutectoid transformation leading to lower rate of carbon diffusion in the ferrite and stabilizing cementite (Fe3C). However, the noticeable problem with Mn addition is that the embrittlement caused during the solidification process and hence limiting its range to (0.3–1.01) [24, 25, 26]. Mn is held between 0.4 and 0.6% when making pearlitic grades and below 0.3% when making ferritic grades and can be achieved by dilution with high purity pig iron to avoid pearlite and carbide formation [25, 26]. Higher Mn content leads to increased pearlite content resulting in increased strength and hardness and decreased elongation, Figure 3. However for a ferritic grade of SGCI Mn dissolved into the ferrite matrix and improves strength [27]. Use of higher Mn level is not preferred as it causes segregation at the grain boundaries that causes grain boundary carburet and creation of secondary phase along the boundaries leading to degradation in plasticity in SG cast iron. In combination with Ni, higher manganese content can stabilize austenite and increases carbide by depressing the solidification cooling curve encouraging graphite to segregate at a lower temperature consequentially resulting lower generation of free graphite and reduced ductility and impact toughness [28, 29, 30, 31].
\n(a) The relationship between tensile strength and elongation versus Mn content (0.05% Cu), (b) average hardness and pearlite content versus Mn content (0.05% Cu) [27].
Sulfur affects the form of carbon in a manner which is opposite to that of Si. The higher the S content, the higher will be the amount of combined carbon, thus tends to form a hard and brittle matrix. An excessive amount of S will increase the tendency of dross defects above 0.015% promote the formation of quasi-flaky graphite [23, 26]. The addition of S is done for better machinability, but it is kept around 0.009, and maximum 0.015% as the larger additions of Sulfur may cause the hot (red) shortness [24]. Sulfur is an active interfacial element and has less solid solubility in austenite, therefore, gets enriched in liquid melt and at the freezing point. The presence of S encourages the eutectic graphite to branch frequently resulting in formation of chunky graphite [32].
\nPhosphorus combines with iron to form iron phosphide and produces a ternary eutectic with cementite and austenite. The ternary eutectic is known as steadite, which is relatively brittle and tends to form a continuous network outlining the primary austenite dendrites resulting lower toughness. It increases fluidity and extends the range of eutectic freezing, thus increasing primary graphitization when Si content is high. Incorporation of P above 0.05% can produce internal defects. It also causes embrittlement of iron, increases the ductile-brittle transition temperature, promotes galvanizing and temper-embrittlement. P often segregates to grain boundaries and produces carbide/phosphide complexes, hence needs to be maintained as low as possible. P is kept intentionally low as it causes cold shortness and so the property of ductile iron will be ruined [24].
\nMagnesium is used as nodulizer and responsible for spherical form of graphite, but at lower level chunky graphites are formed. Like sulfur, it is also an interfacial element and has less solid solubility in austenite. Magnesium makes the eutectic graphite grow with screw dislocations along the crystal orientation, giving the eutectic graphite growth characteristic into a spherical form. The lower level of Mg counteracts the surface activity of sulfur and oxygen promoting the formation and growth of chunky graphite particles. Due to the segregation effect when Magnesium content becomes high enough the graphite shape converts to spherical form [32].
\nChromium prevents the corrosion by forming the layer of chromium oxide on the surface and stops the further exposition of the surface to the atmosphere. However, as it is a strong carbide former, it is not required in carbide free structure. In general it is kept around 0.05%. It must be kept <1% in GGG-50 grade [24].
\nNickel is used for strengthening ferrite in addition to Si leading to increased UTS without compensating ductility and impact values. It is usually added in traces due to high cost and also to avoid the embrittlement of matrix (if it exceeds 2%) [24]. Increased Ni content decreases the ductility for austenitic grade SGCI [33]. Nickel assists in shifting the transformation temperature boundary leading to attention of desired phase at lower temperature when alloyed with Ni as compared to that for an alloy without Ni. Additionally it has the ability to prevent the precipitation of secondary carbides in the final microstructure. Uma et al. [34] studied the effect of toughened austempered SG cast iron with increasing Ni content up to 2.5%. It is reported in their work that, with increasing Ni content pearlite content is increased in the as-cast matrix. Also, the retained austenite gets stabilized in the final microstructure. It is increased due to the fact that Ni concentrates in the austenite phase in the (α + γ) region, resulting in increased impact toughness and wear resistance. When subjected to austempering treatment SG cast iron with Ni content higher than 0.5%, slows down the bainitic reaction and causes the formation of martensite at the austenite cell boundaries on cooling [32]. Although the addition of Ni promotes the stabilization of austenitic matrix in SG cast iron, it accelerates the formation of pearlite by shifting the knee of transformation diagram to higher time intervals. Thus, the eutectoid transformation of ductile cast iron in cooling austenite has resulted in a significant amount of pearlite structure (Figure 4) and decreasing nodularity and nodule count (Figure 5) with increased yield and tensile strength and hardness with decreased ductility as well as impact toughness [35].
\nComparison of constituent content in the microstructure of the Co and Ni alloyed SG cast irons: (a) graphite, (b) ferrite and (c) pearlite [35].
Comparison of nodular graphite of the Co and Ni alloyed SG cast irons: (a) nodularity and (b) nodule count [35].
Copper is a strong pearlite promoter and is undesirable in ferritic grade. It increases the UTS, 0.2% yield strength and hardness (Figure 6) without an embrittlement in the matrix. In total Cu is kept between 0.4–0.8% [24, 25]. Along with promoting, it also refines the slice distance of pearlite in the eutectoid transformation period and is beneficial in stabilizing super-cooled austenite and increases the closing rate of the austenite shell that enables graphite to achieve perfectly spherical shape [27, 32, 36]. Copper strengthens the matrix when Mn levels are low. Unlike Mn, copper has an adverse effect on segregation and usually gathers at the interface between graphite and matrix. As a result, the diffusion of C is restricted due to a higher concentration of Cu, which leads to the formation of perfectly spherical nodules and increased nodule count. The combined effect of Cu and Ni, when subjected to austempering treatment, balances the hardenability, segregation tendency of Mn and inhibits the transformation of untransformed austenite into pearlite during quenching to austempering temperature. An excess amount of Cu results in the evolution of copper or copper-rich phase that affects the mechanical properties [37].
\nRelationship between the mechanical properties and the copper content for different Mn level [27]. (a) Mn content vs. Tensile Strength, (b) Mn content vs. Average Hardness, (c) Mn content vs. % Elongation.
Molybdenum is a mild pearlite promoter and forms intercellular carbides especially in heavy sections leading to increased proof stress and hardness and also improves properties at elevated temperature [24]. Also, Mo segregates at the grain boundaries causing decrease in impact toughness. When subjected to austempering or ausforming process increased amount of Molybdenum stabilizes and increases austenite and bainite content. At zero Mo content the matrix is mainly bainitic, but with the increased amount it also increases the amount of carbide [18]. Mo, with an extreme tendency of segregating to the last solidification area, retards the bainite reaction and causes the micro shrinkage porosity in the intercellular region. Consequently, the Mo alloyed iron offers the lowest impact strength [21].
\nRare earth (RE) materials in the nodulizer can eliminate the bad effect of the interferential elements like titanium, bismuth, arsenic, antimony, etc. and reduce the content of Si and Mg, which is helpful to avoid graphite degeneration. Ferro et al. [38] in their work reported that the graphite structure and nodule count can be improved by a well-dosed amount of RE elements in the inoculant composition. This is caused by a large decrement in surface free energy at liquid/graphite interface due to adsorption on graphite. RE elements also favor the graphite shape due to their neutralization effect of excesses of contaminants which cause nodule degeneration. However excess RE metals may cause graphite deterioration, especially in heavy castings where they form microsegregation at grain boundaries, which can be neutralized by proper addition of Bismuth. In another work by Choi et al. [39] it was reported that addition of rare earth elements influences the formation of ferrite at the vicinity of graphite nodules. The addition of RE increases the ferrite thickness with increased casting thickness due to slower cooling rate than that of castings without RE. However, in the case of thicker casting (40 mm), it does not play any significant role on ferrite formation. Also increasing RE up to 0.02% there was a reduction in nodule size and the nodule size increases with increasing RE from 0.02 to 0.03%. However, the graphite nodule size is further decreased when the RE content is again increased to 0.04%. Furthermore, the presence of RE changes nucleation and growth rate by changing the liquid’s temperature. The addition of RE appears to increase undercooling, as a result of which its nucleation rate is increased, but the growth rate is decreased. Rare earth elements like lanthanum increases nodule count with increasing content when La to S ratio is as low as 1, hence increases the strength and ductility. However, it does not show any significant development in the nodularity value, which remains almost constant with increasing La amount [21].
\nIn our study to investigate the structure–property relationship, ductile iron test blocks were prepared with different alloying elements and chemical composition by weight percentage is presented in Table 1. To investigate the mechanical and tribological properties specimens of 25 × 10 × 5 mm3 were machined from the test block and then austenitized at 1000°C for 90 min followed by quenched in KNO3 + NaNO3 (1:1 ratio) at 500°C. The specimens were kept in the salt solution at 500°C for 4 h so as to obtain complete transformation of as-cast matrix. Post quenching the specimens were cooled to room temperature via air cooling, followed by the oxide layer formed on specimen surface was removed by conventional filing and emery paper polishing method.
\nElements | \nWt. % | \n|
---|---|---|
Alloy 1 | \nAlloy 2 | \n|
C | \n3.45 | \n3.61 | \n
Si | \n2.07 | \n2.1 | \n
Mn | \n0.15 | \n0.2 | \n
S | \n0.008 | \n0.007 | \n
P | \n0.024 | \n0.022 | \n
Cr | \n0.02 | \n0.03 | \n
Ni | \n0.15 | \n0.47 | \n
Cu | \n— | \n0.009 | \n
Mo | \n— | \n0.001 | \n
Mg | \n0.043 | \n0.043 | \n
Ce | \n— | \n0.004 | \n
Fe | \nBalance | \nBalance | \n
Chemical composition of specimens in wt.%.
The as-cast and austempered specimens are subjected to hardness measurement with the help of a Vickers hardness tester by applying 20 kg load and keeping indenter on the surface for 10 s. Tribological properties were investigated by employing wear test on Ducom TR-208-M1 Ball on plate type wear tester consisting of a 0.4 mm spherical tipped diamond cone indenter of 120° angle. The wear test was conducted at 3 different loads of 10, 20 and 30 N and the travel distance being 7.54 m at a linear velocity of 0.063 m/s. The weights for corresponding specimens before and after test was measured with the help of electronic balance with 0.1 mg accuracy, and prior to the weight measurement specimens were cleaned ultrasonically with acetone before and after the wear took place.
\nThe working principle for ball on plate wear tester is very much similar to that of pin on disc equipment. The only difference between both of the equipment is, the specimen in the pin on disc is in the form of cylindrical pin and the disc on the counterpart rotates against it, where the load is applied on the specimen end. On the other hand, in case of ball on plate the specimen is fixed on the rotating plate and the indenter being fixed as well as load is applied on this end.
\nTo understand the wear behavior of respective as-cast and austempered specimens’ morphological examination was carried out for microstructural aspects. The specimens were initially underwent rough polishing using belt polisher followed by semi finishing polish with 1/0, 2/0, 3/0, 4/0 grades of emery paper and alumina slurry polishing using cloth polisher. The final polishing was carried out using 1 μm diamond paste with the help of cloth polisher. The specimens were observed under microscope in unetched condition to investigate the graphite morphology and distribution in respective a-cast and austempered specimens. And after that each specimen was etched with 2% Nital solution and observed under microscope to obtain the phase characteristics and distribution in the matrix. Additionally the as-cast and austempered specimens subjected to X-ray diffraction investigation for detection of any impurity or precipitation resulted during casting or heat treatment process.
\nThe worn surfaces of respective as-cast and heat treated specimens for both the alloys were observed under optical microscope after the tribology test. The worn surfaces also observed under FESEM and EDAX to understand the wear phenomena and the presence of any foreign element contributing toward the tribological behavior.
\nThe XRD investigation, Figure 7, revealed that there is no trace of any kind of residual phases or precipitation of any impurity present in the final microstructure. It was noticed that only BCC crystallographic planes (110), (200) and (211) are present in the as-cast specimen (Figure 7(a)) justifying ferrite and pearlite matrix. On the other hand BCC (110) and (211) and FCC (311) planes were observed for austempered specimens (Figure 7(b)) justifying bainitic matrix that is a combination of austenite and ferrite resulted due to the quenching and cooling processes in salt solution and ambient air respectively. The quantitative analysis shows higher carbon content as well as austenite volume fraction for Alloy 2 resulted due to the present of significantly higher amount of Ni as compared to Alloy 1, which act as austenite promoter during the austenitization stage and also helps in retaining the phase during the transformation process to the room temperature microstructure [40].
\nX-ray diffraction pattern for respective specimens. (a) As-cast and (b) austempered.
The microstructures of as-cast and austempered specimens for Alloy 1 and Alloy 2 were illustrated in Figure 8. The as-cast matrix of Alloy 1 (Figure 8(a)) appeared to have a mixture of ferrite, the white areas around graphite nodules and pearlite, the black area surrounding the white ferrite area in nature. This structure is referred as bull’s eye ferritic/pearlitic one with graphite nodules surrounded by ferrite. On the other hand, microstructure of Alloy 2 (Figure 8(b)) has fully ferritic in nature surrounding the graphite globules. The difference is attributed to higher amount of Si content which is a strong ferrite promoter [41]. Figure 8(c) shows the coarse upper bainitic microstructure resulted by austempered heat treatment process. Quantitative metallographic analysis illustrates that nodularity (roundness of graphite particles) is above 90% that belongs to the Grade I nodularity, for both as-cast and heat treated specimens in both the alloys. The graphite characteristic (nodularity) and distribution (nodule count) for respective alloys in as-cast as well as austempered condition is presented in Table 2. It can be observed that Alloy 1 has less no. of nodules than Alloy 2, resulted due to lower Si content and additional Ce as well as higher Ni content in the latter case [42, 43]. The quantitative analysis also reveals the higher bainite volume fraction for Alloy 2 as a consequence of higher Ni content, as was observed from quantitative X-ray diffraction analysis.
\nMicrostructure of as-cast and austempered specimens. (a) As-cast matrix for Alloy 1, (b) as-cast matrix for Alloy 2, and (c) austempered matrix for both Alloy 1 and Alloy 2.
Alloy | \nHeat treatment | \nNodularity (in %) | \nNodule count (mm−2) | \nPhase volume fraction (in %) | \nCarbon content in austenite | \n|
---|---|---|---|---|---|---|
Austenite | \nFerrite | \n|||||
Alloy 1 | \nAs-cast | \n92 | \n28 | \n— | \n— | \n— | \n
Alloy 2 | \n95 | \n33 | \n— | \n— | \n— | \n|
Alloy 1 | \nAustempered | \n91 | \n43 | \n70.00% | \n30.00% | \n2.5387 | \n
Alloy 2 | \n93 | \n50 | \n88.51% | \n11.49% | \n2.5941 | \n
Microconstituents of as-cast and austempered specimens of respective alloys.
The Vickers hardness value for the as-cast and austempered specimens of both Alloy 1 and Alloy 2 are presented in Figure 9. The hardness was found to be higher for austempered specimen with upper bainitic matrix as compared to the as-cast ferritic and ferritic + pearlitic specimens. Alloy 1 has higher hardness in as-cast condition as compared to Alloy 2 which is credited to the amount of pearlite in the matrix, whereas Alloy 2 has only ferritic matrix in nature. On the other hand the case is reverse for austempering treated specimens, i.e., Alloy 2 has higher hardness value than Alloy 1 because of higher amount of Ni in the former resulting combination of higher amount of austenite and eutectoid ferrite in the matrix.
\nVickers hardness for respective as-cast and austempered specimen.
The wear system appears to have resulted in variation of weight loss/gain with variation of applied load for respective as-cast and austempered specimens and decreases continuously for as-cast specimen when load was increased from 10 to 20 N. On the contrary upon increase in load to 30 N a gain was observed which might be due to hardening of surface when operating under repeated no. of cycles. On the other hand, weight gain was observed for austempered specimens when operating under 20 and 30 N. On comparing with hardness values for respective specimens the weight loss at 10 N was observed to be lowest for the specimen with higher hardness value consequence of pearlite in the matrix [44]. The effect of matrix was appeared to have direct effect on the wear rate, where the hardness was higher for bainitic matrix and the wear rate is less as compared to the ferritic and ferritc/pearlitic specimens with lower hardness with higher rate of wear. At 20 N load upper bainitic matrix showed a marginal gain in weight, but as-cast specimen had significantly lose some weight. Further at 30 N again weight gain was observed for both austempered and as-cast specimen.
\nTo understand the wear mechanism involved in due process the worn surfaces for respective as-cast and austempered specimens of both alloys were observed under optical as well as finite element scanning electron microscope and illustrated in Figures 10 and 11 respectively. The direction of tool travel or wear direction is represented by green arrow for the as-cast and austempered specimens (Figure 10). The principal wear mechanism for as-cast and austempered specimens was found to be mostly adhesive wear in nature for all loads. Micro cracks were observed while operating under 10 N for as-cast specimens (Figure 10(a)) along with delaminated layer initiated for the soft matrices [45, 46]. Shallow pits and broken wear platelets were also appeared on the surface caused by delamination and work hardening, which was deposited over the graphite nodules. Upon increase in load to 20 N and running for a longer cycles the delaminated layer were observed to be deposited over the graphite nodules (Figure 10(b)). The graphite nodules were also observed to expand in transverse direction of wear along with shear deformation [47]. On further increment of load to 30 N (Figure 10(c)) the micro cracks were appeared to broaden and surface becomes flat as well as free of wear debris. The wear surface for the austempered specimen under 10 N (Figure 10(d)) on the other hand does not have any cracks formed and appeared to be flat in nature with no specific characteristics. The result can be attributed to the hardness of austempered specimen resulting increased wear resistance and work hardening at an early stage. Upon increase in load to 20 N (Figure 10(e)) cracks were initiated at the surface as well as small amount of plastic deformation was observed to be involved that might be due to the attention of plastic stage while running under such high load for a large cycle [48, 49]. The plastic deformed feature was observed to be pulled out (Figure 10(f)) of the surface upon continuous frictional effect aroused upon increase in load to 30 N. After such a long run the wear surface does not appear to have any crack on it which is probably due to the particle pull out phenomena resulted through plastic deformation, hence the mechanism involved in this case also classified as adhesive wear.
\nOptical microscopy investigation of worn surface of respective specimen at varying load condition. (a) As-cast specimen under 10 N; (b) as-cast specimen under 20 N; (c) as-cast specimen under 30 N; (d) austempered specimen under 10 N; (e) austempered specimen under 20 N and (f) austempered specimen under 30 N.
FESEM and EDAX observation for respective specimens with oxide layers. (a) As-cast specimen under 30N, (b) Austempered at 20N load, (c) Austempered at 30N load.
To investigate the presence of any impurity or foreign contamination the worn surfaces of respective specimens were investigated under NOVA NANOSEM 450, field emission scanning electron microscope, with EDAX analysis feature. The as-cast specimens under 10 N and 20 N did not have any significant characteristics on the surface. However at 30 N load the surface appears to have oxide particles present revealed by the FESEM image (Figure 11(a)). On the other hand for austempered specimen the oxide particles were observed for both 20 N (Figure 11(b)) and 30 N (Figure 11(c)). The oxide particles were observed at different places on the wear ring, and that is responsible for the weight gain as observed in the investigation. The respective areas of oxide presence are shown by red rectangles in respective FESEM images along with the EDAX composition analysis at that particular area. The width and depth of wear track was increased with increase in load as well as responsible for reduction in the crack length for respective specimens. The worn surface features are found to be distinctive for 30 N load as compared to 10 and 20 N. The as-cast specimens appeared to have plowing mark at various places and graphite nodules are also observed to start disrupting from their original shape, confirming adhesive wear mechanism. Figure 12depicts the EDAX spectrum of austempered specimen under 30 N load showing the highest peak of oxygen along with Fe.
\nEDAX of austempered specimen showing oxides when operated under 30 N load.
The wear behavior of as-cast pearlitic/ferritic ductile iron was compared with upper bainitic austempered specimens with different alloy composition. From investigation the following conclusions can be drawn:
Austempering at higher temperature leads to transformation of as-cast ferritic and pearlitic/ferritic matrix for both alloys into coarse upper bainitic matrix and increases the hardness.
Soft ferritic matrix was less resistant to wear due to lower level of hardness, whereas austempered coarse upper bainitic matrix with higher hardness value was more resistant to wear.
A considerable gain in weight was observed for austempered specimen at 20 N load, whereas the normalized specimen does not show any weight loss or weight gain.
Adhesive wear phenomenon was observed for specimens with soft ferritic matrix along with micro cracks due to the hardening of surface while operating under high load and kept on increasing with increase in load.
The worn surface when subjected to 10 N load did not show any significant features for austempered specimens, but on the contrary fro as-cast soft phase matrices showed plowing micro cracks and delamination features. On the other hand for 30 N loading condition delaminated layer deposition over graphite particles were observed for as-cast specimen and austempered specimen showed particle pull phenomena along with breaking of wear continuity. Under all the loads the wear phenomenon was observed to be adhesive type wear.
\n spheroidal graphite cast iron ductile cast iron austempered ductile iron
Nigeria often referred to the giant of Africa is the largest Black nation in Africa. It is a country located in West Africa bordered by Cameroon in the East, Benin Republic in the West, Niger Republic to the North and Chad Republic to the North East. It is a federation consisting of 36 states with Abuja the Federal Capital territory as the capital. It is located on the Gulf of Guinea with a total area of 923,768 km2 (356,669 sq. miles). It is the world’s 32nd-largest country. Nigeria got her independence from the British on 1st of October 1960. It has an estimated population of over 200 million people. The United Nations estimated the population in 2016 to be 185,989,640 distributed as 51.7% rural and 48.3% urban with a population density of 167.5 persons per square kilometre. Although the official language is English, there are more than 250 ethnic groups with well over 500 different native languages and diverse cultures. There are 3 major ethnic groups in Nigeria (Hausa/Fulani, Igbo and Yoruba). Nigeria is a religiously diverse nation divided into a predominantly Christian South and Muslim North and a minority groups of traditional African religion. Nigeria is a mixed economy dependent and an emerging market. As at 2014 Nigeria was the fastest growing and largest economy in Africa. She is blessed with abundant natural resources and a developing communication, financial, legal and transportation sector. Nigeria is the 12th largest producer of oil in the world, the 8th largest exporter, has the 10th largest proven reserves and supplies a fifth of its oil to the United States of America. Oil plays a significant role in the Nigerian economy and accounts for 40% of GDP and 80% of all government earnings. Healthcare delivery is the responsibility of the 3 tiers of government (federal, state and local government). There is a number of health-related challenges in Nigeria (HIV/AIDS, malaria, polio, poor access to potable and clean water, lack of proper sanitation system, high infant and maternal mortality rates). Although the recurrent expenditure on health in Nigeria has increased over the years, healthcare delivery and infrastructural endowment remains suboptimal with health tourism on the increase [1]. The Nigerian health care system is continuously faced with a number of challenges; shortage of healthcare workers [2] predominantly due to significant emigration of skilled medical personnel to developed economies of the world (brain drain), suboptimal funding, decaying infrastructure, inter-professional conflict, perennial strike actions by healthcare professionals, lack of political will as well as bureaucratic bottlenecks in public health care delivery in Nigeria [3].
\nNigeria is a party to the United Nation (UN) General Assembly adopted 2030 agenda for Sustainable Development and the UN High-Level Meeting (UN HLM) Universal Health Coverage (UHC) UHC2030. In September 2015, the UN General Assembly adopted the 2030 Agenda for Sustainable Development that included 17 Sustainable Development Goals (SDGs) ensuring that all persons are carried along and that no one is left behind [4]. The agenda laid emphasis a holistic approach aimed at achieving sustainable development for all. The 17 sustainable development goals (SDGs) included; no poverty, zero hunger, good health and well-being, quality education, gender equality, clean water and sanitation, affordable and clean energy, decent work and economic growth, industrial innovation and infrastructure, reduced inequality, sustainable cities and communities, responsible consumption and production, climate action, life below water, life on land, peace and justice strong institutions and partnerships to achieve goal. On September 23rd 2019, a high-level meeting on universal health coverage held at the United Nations General Assembly. The meeting focussed on Universal Health Coverage: Moving Together to Build a Healthier World (UHC2030) and brought together heads of state, political and health leaders, policy-makers, and universal health coverage champions to advocate for health for all. The meeting agreed on Key Asks from the UHC Movement aimed at accelerating progress toward Universal Health Coverage (UHC) [4]. Among others, UHC2030 advocates that countries should; ensure political leadership beyond health (that all countries to ensure healthy lives and wellbeing for all at all stages as a social contract), leave no one behind (pursue equity in access to quality health services with financial protection), regulate and legislate (create a strong, enabling regulatory and legal environment responsive to people’s needs), uphold the quality of care (build high-quality health systems that people and communities trust), invest more and better (increased domestic investment and allocation of more public financing for health through equitable and mandatory resource) and move together (establishing multi-stakeholder mechanisms for engaging the whole of society for a healthier world). Nigeria is a party to the global commitment ensuring the well-being, universal health coverage and access to quality healthcare when and where they need it, without facing financial hardship [5]. There is general expectation among Nigerians for the government to mix word with action by ensuring that all Nigerians in both rural and urban communities have access and can use the promotive, preventive, curative, rehabilitative and palliative health services they require, that is of sufficient quality and affordable [6].
\nThe human red blood cell membrane is complex and contains a number of clinically relevant blood group antigens, the most relevant being the ABO and the Rhesus blood group antigens. Apart from the ABO and Rhesus blood group systems, thirty-four other blood group systems have been identified as at November 2014 [7]. In addition to the ABO and Rhesus blood group antigens, 364 other red cell antigens have been identified serologically. The clinical relevance of a blood group system depends on the distribution of antigens of the blood group system in the population, ability of antibodies of the blood group system to cause haemolytic transfusion reaction (HTR) and haemolytic disease of the foetus and newborn (HDFN) [8]. The ABO blood group system is one of the most clinically relevant blood group systems [9]. It was first discovered by Karl Landsteiner in 1901 [10]. The ABO blood group system has three main antigens (A, B and H). Four major ABO groups exist (A, B, AB and O). The ABO blood group system is based on the A and B antigens occurring singly as A or B, doubling as AB or the absence of both as O. Individuals who have lack the A or B antigens on their red cells have the group specific antibody in their serum or plasma. Antibodies of the system are predominantly IgM originally thought to be naturally occurring but are now known to occur in the first years of life as a result of sensitization to ABO-like antigen and environmental substances that occur in nature such as bacteria, viruses and food. Evidence has shown that these antibodies are not present at birth and that animals kept in a sterile room from birth do not produce these antibodies. The ABO blood group system is important in transfusion medicine, HDFN and in organ transplant. Transfusion of ABO incompatible unit can cause severe HTR. Similarly, an immune response can also occur following ABO incompatible organ transplant. ABO blood group incompatibilities between the mother and child does not normally cause HDFN because antibodies of the ABO blood group system are usually of the large molecular weight IgM type, which do not cross the placenta. However, mothers who were previously sensitised (previous incompatible transfusion and pregnancy) can potentially have IgG ABO antibodies that can potentially cause ABO HDFN. The distribution of ABO blood groups varies across the world according to the population. There are also variations in blood type distribution within human subpopulations.
\nNigeria is a significantly varied nation in terms of ethnicity. The gene frequency of ABO and Rh blood group varies significantly within the six geopolitical zones in Nigeria [11, 12, 13, 14, 15, 16, 17, 18]. Previous studies in most parts of Nigeria indicates that the ABO blood group distribution is in the order O > A > B > AB [19]. Studies from the United States, Mauritania, Morocco, Cameroun, Tunisia, Ethiopia and Iran reported same order (O > A > B > AB) [20, 21, 22, 23, 24, 25, 26]. However, study in Madagascar and Guinea reported a contrary trend (O > B > A > AB) [27, 28]. This observation in Nigeria is also at variance with reports from India and Bangladesh where prevalence of B is highest followed by O and the least was AB (B > O > A > AB) [29, 30]. Reports from Turkey and Colombia indicates an order A > O > B > AB [31, 32].
\nA multi race/ethnic study in the United States reported that blood type O is the most prevalent (46.6%) with White non-Hispanic, Hispanic, Black non-Hispanic, Asian and North American Indian having varying percentage of 45.5, 56.5, 50.2, 39.8 and 54.6 respectively [21]. Other studies in Turkey, Mauritania, Iran, Ethiopia, Colombia, Cameroun, Bangladesh, Madagascar, Morocco, Guinea and Northern India have reported varying percentage in ABO and Rh blood types [20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32].
\nPhenotypic distribution of Rh(D) in Nigeria varies from one part of the country to the other; Kwara (4.5%) [17], Jos Plateau State (4.32) [14], FCT (4.3) [33], Minna (3.3%0) [11], Lagos (3.0, 6, 6.86%) [16, 34, 35], Ogun (6.65 and 2.9%) [36, 37], Osun (6.3%) [38], Oyo (3.3, 6.68, 4.8, 5.89%) [12, 14, 18, 39], Ekiti (4.3%) [40], Akwa Ibom (5.7%) [41], Bayelsa (2%) [42], Delta (1.8%) [43], Benin (6.0%) [13], Rivers (3.2, 7, 8.3%) [44, 45, 46], Kano (5.2%) [47], Sokoto (1.55%) [14], Zamfara (1.2%) [48], Enugu (4.49%) [14], Abia (5.3%) [49], Ebonyi (4.2%) [50], Borno (1.92%) [14], Adamawa (4.6%) [51], Yobe (4.6%) [52]. The prevalence of Rhesus negativity varies from one zone to the other; 4.4, 3.1, 6.0, 4.3, 3.9 and 3.1% respectively for the South East, North East, South, South, South West, North Central and North West zone respectively.
\nThe overall average prevalence of Rhesus negativity is 5.1%. The distribution of Rh(D) in Nigeria is in agreement with others parts of the world [20, 23, 25, 26, 27, 28, 30, 31]. Blacks have been found to have a lower frequency of Rhesus D negative phenotype (3–5%) [34, 42, 44] compared to the general Caucasian population (15%) [21, 53]. The lower prevalence of Rh(D)− in Nigeria and other developing is important and a blessing in disguise because clinical situations like fetomaternal haemorrhage during the course of pregnancy can give arise through Rh incompatibility and HDFN. In Nigeria and many of these developing countries RAADP and other anti-D HDFN related prevention strategies are not being implemented. Table 1 shows the prevalence of Rhesus D group among Nigerians based on zones.
\nZone of Nigeria | \nPercentage of Rhesus negative status | \nPercentage of Rhesus negative status | \n
---|---|---|
South-East | \n4.4 | \n95.6 | \n
South-South | \n6.0 | \n94 | \n
South-West | \n4.3 | \n95.7 | \n
North-East | \n3.1 | \n96.9 | \n
North-West | \n3.1 | \n96.9 | \n
North-Central | \n3.9 | \n96.1 | \n
Prevalence of Rhesus D group among Nigerians based on zones.
The Kell blood group is the third most clinically relevant blood group system after ABO and Rhesus. Individuals without Kell antigens (K0) who are transfused with Kell positive donor red cells or Kell negative pregnant women exposed to the Kell positive red cells of their baby carry the risk of developing Kell antibody which can cause HDFN [54]. In the developed world all pregnant women and non-pregnant women of child bearing age are transfused with Kell negative blood. Also, patients with other antibodies are transfused with Kell negative and red cells also lacking the antigen to which their alloantibody is specific. This is to prevent them from potentially developing anti-Kell antibody. Kell sensitization is the third most common cause of HDFN after Rh and ABO. Anti-Kell has been shown to cause severe foetal anaemia by suppressing foetal RBC synthesis [55]. HDFN-associated anaemia in Anti-Kell-related HDFN is caused by the ability of anti-K to cause the suppression of foetal production of RBCs [56]. Unlike Rh and ABO, Kell antigens are expressed on the surface of RBC precursors, and anti-K promotes the immune destruction of Kell positive erythroid early progenitor cells by macrophages in the foetal liver rather than only mature foetal RBCs [55]. There are few Kell prevalence studies in Nigeria. Among their cohort of pregnant women in Sokoto, North Western Nigeria, Erhabor and Colleagues [57] obtained a Kell antigen prevalence of 2%. Similarly, Ugboma and Nwauche [58] in Port Harcourt investigated the prevalence of Kell antigen among their patients and reported a Kell antigen prevalence of 2%. The prevalence of Kell antigen among a multi-ethnic cohort of 302 healthy Nigerian individuals indicated a zero prevalence of K antigen [59]. Racial differences seem to exist in Kell blood group antigen distributions [60, 61]. The Nigerian government and governments in other African countries will need to implement this strategy in a bid to reducing Kell-related sensitization and the effect of HDFN.
\nThe prevalence of other clinically significant red cell antigens has been determined among Nigerians. The prevalence of Lewis, Kidd, Duffy, Kell and M blood group antigens among blood donors in Aminu Kano Teaching Hospital, Kano, Nigeria [62] were as follows: Lea: 26.4%, Leb: 15.1%, M: 20.8%, k (cellano): 21.7%. The Duffy (anti Fya, anti Fyb) and Kidd (anti Jka anti Jkb) antigens were not detected among the donors. Out of the 162 pregnant women tested for their Duffy antigens status indicated Fya, Fyb and Fya (a+b+) prevalence of 7 (4.3%), 9 (5.6%) and 1 (0.61%) respectively [63]. Kidd blood group phenotypes were determined among pregnant women in Sokoto, North Western Nigeria [63]. The distribution of Kidd antigens among subjects studied indicated a prevalence of Jka, Jkb and Jk(a+b+) of 8 (4.9%), 13 (8.0%) and 0 (0.0%), respectively. There is need for the phenotyping of donor’s blood for clinically significant red cell antigens. There is also the need to routinely screen all pregnant women for alloantibodies to facilitate the selection of antigen negative units for those with clinically significant alloantibodies who require a red cell transfusion. This can potentially optimise the obstetric management of HDFN.
\nThe prevalence of Rh c and e phenotype among 200 pregnant women attending antenatal clinic (ANC) in Usmanu Danfodiyo University Teaching Hospital Sokoto was determined. The prevalence of Rh c was 92% while Rh e was 98.5% [64]. The frequencies of Rh blood group antigens and phenotypes of the Ibibio, Efik, and Ibo ethnic nationalities in Calabar municipality, Nigeria, were determined using standard serologic techniques. Of the 720 Calabar individuals tested, the frequencies of the Rh antigens within the nationalities were c (100%), e (96.38%), D (96.38%), E (15.22%), and C (3.62%) for the Ibibios; c (100%), e (95.60%), D (96.70%), E (21.98%), and C (0%) for the Efiks; and c (100%), e (94.29%), D (91.43%), E (28.57%), and C (2.86%) for the Ibos. The overall frequencies of the Rh antigens in these 720 individuals were c (100%), e (95.56%), D (94.44%), E (18.89%), and C (2.78%). Forty (5.56%) were found to be D−, while all were found to possess the c antigen. The most frequently occurring Rh phenotype was Dccee, with a frequency of 73.61%. The alternative allele, C, did not appear in homozygous form (CC) in the population tested [65]. Of the 374 pregnant women studied in Port Harcourt, Nigeria, the frequencies of the Rh antigens within the population were D (89.0%), c (82.0%), e (54.0%), C (24.3%), E (20.1%). The frequencies of the Rh antithetical antigens were DD/Dd (91.2%), Cc (19.5%), cc (84.5%), Ee (13.9%), ee (54.3%), CC (25.1%), EE (19.8%) and dd (10.4%). Seven (1.9%) were found to be Rhnull, sixteen (4.3%) were found to be D− or exalted D. Phenotypes without RhD reactivity were -c- (2.9%), -Cc (0.3%), -C- (0.3%), -Ee (0.5%) and -E- (0.3%) [66]. A multi-ethnic cohort of healthy Nigerian individuals were studied. The antigen status of these individuals for Rh was determined. The prevalence of the Rh antigens in the study cohort was found to be: D (92.7%), C (20.5%), c (97.7%), E (19.5%), and e (97.4%). Dce was the most common Rh phenotype (53.3%) [59]. Few countries in sub-Saharan Africa have systematic testing for antigens C, c, E, and e of the Rh and Kell system antigens in the donor and recipient, thereby exposing transfused patients to the risk of developing antibodies that can cause HTR and HDFN. Among 651 blood donors tested in Abidjan for antigens of the Rh blood group system, the antigen frequencies of D, c, e, C, and E were; 92.93, 99.85, 99.85, 21.97, and 13.82% respectively. K antigen is was found in 0.77% of donors [67].
\nABO blood group system is one of the most clinically relevant blood group systems. Individuals above the age of 6 months have clinically significant anti-A and/or anti-B in their serum particularly if they lack the corresponding antigens on their red cells. Whole blood transfusion still thrives in Nigeria despite the advantages of component therapy and challenges associated with whole blood transfusion (development of febrile transfusion reactions, graft-versus-host disease, alloimmunization to leukocyte antigens, immunomodulatory effects, transmission of diseases such as cytomegalovirus, Human T-Lymphotrophic Virus I/II and Epstein Barr (EBV) for which leukocytes may be the vector) [68]. Blood group O donor blood is the most common blood group among Nigerian blood donors [69] and their red cells are commonly used as universal donor units for transfusion to A, B and AB recipient particularly in emergency situations. Blood group O individuals lack the A and B antigens on their red cells and thus are inappropriately called Universal donors. These individuals have anti A and Anti B in the plasma. Due to the absence of A and B on their red cell, their red cells could be given to A, B, and AB individuals. This is quite useful particularly in Nigeria and other developing countries where there is inadequate supply of donor blood. However, some group O individuals have potentially lytic anti-A and lytic anti-B in their plasma that bind to antigens A and B on the surface of erythrocytes in recipients and potentially activate the complement cascade resulting in acute intravascular haemolysis. To avoid this, all blood group O donor units intended for transfusion to non-O patient must be tested for the presence of these anti-A and lytic anti-B haemolysis. Those donors found negative can have their blood given to non-O patients while those that test positive are reserved for group O recipients only. Haemolysin testing to identify the presence of haemolytic anti-A and anti-B antibodies has emerged as a useful screening in most countries to identify high levels of anti-A and/or anti-B antibodies to prevent HTRs. Routine haemolysis testing of blood group O donor units intended for transfusion to A, B or AB recipient is not routinely carried out in most settings in Nigeria despite the high prevalence of haemolysins observed among Nigerians in previous studies [70, 71, 72, 73, 74, 75]. The Nigeria government can learn from evidenced-based best practices in most developed settings [76, 77] and implement a policy to routinely test all group O donor units for haemolysins in other to identify group O donors with high titre of IgG anti A and/or anti B whose blood should be reserved only for transfusion to group O recipient while those that test negative can be transfused to A, B or AB individual as a way to maximising the use of our limited allogeneic stock.
\nAlloantibodies are antibodies produced in a patient as a result of exposure to foreign red cell antigen via transfusion, pregnancy or transplantation. In countries such as Nigeria, there are multiple ethnic groups and racial or genetic heterogeneity among the population. This can often be associated with a wide variation of alloantibodies [78]. Other common factors that facilitate alloantibody formation in the recipient include: the immune competence, the dose of the antigen the recipient is exposed to, the route of exposure and how immunogenic the foreign antigen is [79, 80]. Development of alloantibodies can lead to difficulty in finding compatible blood for transfusion or it can result in severe delayed haemolytic transfusion reaction if the antibody titre is low, undetected, missed and if antigen positive units is transfused [81]. Evidenced-based best practice in the developing world requires that alloantibody testing is carried out as part of pre-transfusion testing of patients who require a red cell transfusion as well as pregnant women presenting to antenatal clinic at booking [82, 83]. The aim of this test is to detect the presence of unexpected red cell antibody in the patient’s serum [84, 85]. Once these antibodies are detected during the alloantibody screening, every effort must be made to identify the specificity of the alloantibody by doing a panel test. The aim of identifying the specificity of the alloantibody in a patient that requires a red cell transfusion is to enable the Medical Laboratory or Biomedical Scientist to select antigen negative donor unit for appropriate crossmatch (indirect antiglobulin test) for such patient [86]. The aim of a panel test in the case of a pregnant women coming for antenatal booking is to identify the alloantibody, determine whether the antibody can potentially cause HDFN [87] and to allow the monitoring of the titre or quantification of the antibody every 4 weeks from booking until 28 weeks’ gestation and every 2 weeks thereafter until delivery [88]. The obstetrician requires this information to determine to what extent the developing foetus is affected by HDFN, decide whether to monitor the baby for anaemia using Doppler ultrasound, determine whether the baby will require intrauterine transfusion and to make an informed decision to possibly deliver the baby earlier. These evidence-based best practices are not being implemented in many settings in Nigeria. Testing of donor units for other clinically relevant red cell antigens other than ABO and Rhesus D is not routinely carried out. Also, donor units particularly those intended for transfusion to pregnant women and neonates are also not routinely screened for CMV and Hepatitis E virus like it is routinely done in more advanced part of the world. This is a complete failure in stewardship by the Nigerian government and can compromise the transfusion service delivery to pregnant women and patients that require red cell transfusion.
\nRAADP or routine antenatal anti-D prophylaxis is a recommended treatment option for all Rhesus D negative pregnant women who are not known to be sensitised previously to the RhD antigen. The D antigen is the most immunogenic and most clinically relevant of the Rhesus antigens. A mother who is RhD negative and married to a homozygous or heterozygous D positive husband has a 100 and 50% chance respectively of carrying a D positive baby. During such pregnancies as a result of feto maternal haemorrhage (FMH) following potentially sensitising events [abdominal trauma, abortion or termination of pregnancy, antepartum haemorrhage (APH), amniocentesis, chorionic villus sampling, external cephalic version (ECV) and miscarriages] during pregnancy, small amounts of foetal blood can enter into the maternal circulation. The foetal RhD-positive cells can irreversibly sensitise the mother to produce alloantibody D. The risk of sensitisation occurring is dependent on a number of factors; ABO blood group of the developing foetus (there is a higher risk if there is ABO compatibility between mum and baby), dose of foetal cells entering the maternal circulation, immune competence of the mother and type of pregnancy (risk is significantly higher in the first decreasing in the subsequent pregnancies. The antibody produced is immune IgG antibody that is a low molecular weight antibody and can potentially cross the placenta barrier. The maternal immune anti-D are small molecular weight IgG immunoglobulin and can pass through the placenta in subsequent D positive pregnancy and destroy the foetal red cells with increased production of bilirubin a product of red cell breakdown (HDFN). While in womb the mother manages the bilirubin on behalf of the baby by production of glucoronyl transferase enzyme which break down (conjugate) the bilirubin to water soluble forms that can be excreted in the urine. However, after delivery, the excess bilirubin released from the breakdown of the foetal red cells leads to jaundice. With the baby’s liver poorly developed and not producing enough glucoronyl transferase enzyme to conjugate the bilirubin to excretable form, the level can potentially rise above the blood brain barrier and cause kernicterus (permanent brain damage) with attendant neurodevelopmental problems (cerebral palsy, deafness neuromotor and speech delay). Routine antenatal anti-D prophylaxis (RAADP) is a program under which Rhesus D negative non-sensitised pregnant women are universally offered anti-D prophylaxis at 28–34 weeks’ gestation with the aim of preventing the sensitization of Rh D-negative women and by extension prevent anti-D HDFN in subsequent pregnancy [89]. The aim of the RAADP programme is the reduction in the incidence of anti-D related HDFN; improve the survival of the children delivered by Rhesus D negative women, reduce the incidence of disability and health-related quality of life of children and mortality in children delivered by Rhesus D negative women who would have developed anti-D related-HDFN if mothers were not offered prophylaxis. The RAADP program is based on offering either two doses of at least 500 IU at 28- and 34-weeks’ gestation or a single dose of at least 1500 IU at 28 weeks gestation followed by a further dose of at least 1500 IU within 72 h of delivery of a Rh D positive baby. The dose offered post-delivery is dependent on the result of feto maternal haemorrhage testing result (flow cytometry of Kleihauer testing). Both methods quantify in millilitres the amount of foetal red cells that has entered maternal circulation to facilitate the administration of adequate dose of prophylactic anti-D. As a general rule 1 25 IU of anti-D is administered to clear 1 ml of foetal red cells from maternal circulation. The introduction of anti-D prophylaxis using Rhesus D immunoglobulin (given intramuscular or intravenous administration) has led to a significant fall in the number of women becoming sensitised and by extension reduced the incidence and severity of this condition. The anti D immunoglobulin used as prophylaxis is prepared from plasma of male Rhesus D negative donors who have high levels of plasma anti-D due to deliberate or intentional immunisation with D positive red cells. Anti D is also administered to Rhesus D negative women following a potentially sensitising events during pregnancy. The anti-D facilitates the clearance of foetal red cells from the maternal circulation to prevents active immunisation, thus preventing the production of alloantibody D. Prior to the availability and widespread use of anti-D prophylaxis for Rhesus negative pregnant women, the incidence of Rh D sensitization among Rhesus D negative women following two deliveries of D positive and ABO-compatible, infants was approximately 16% and haemolytic disease of the foetus and newborn (HDFN) due to immune anti-D was a significant cause of morbidity and mortality [90]. Following the implementation of anti-D prophylaxis, the rate of sensitization has declined significantly to approximately 2%. With the implementation of RAADP by providing anti-D prophylaxis in the 3rd trimester between 28 and 34 weeks gestation, there has been a further remarkable reduction in the sensitisation rate to 0.17–0.28% [91]. Mortality from D-related HDFN related has also declined significantly from 46/100,000 births to 1.6/100,000 births [89]. Evidence from best practice implementation in England and Wales indicates that RAADP has reduced the incidence of sensitisation and hence of HDFN [92]. Conservative estimate indicates that it cost £2–£3.5 million for England and Wales to provide RAADP to all her Rh D-negative pregnant women. The Nigerian government can learn from this evidence-based best practice by implementing RAADP program for her population of Rhesus D negative pregnant population with the hope of reducing sensitization, incidence and severity of anti-D related HDFN and mortality in Nigeria.
\nRhesus D grouping is relevant for blood donors, transfusion recipients and for women of child bearing age including pregnant women. This is because the Rh blood group antigens particularly D is significantly immunogenic. Rh D negative individuals often lack the D antigens on their red cells and can potentially be sensitised when exposed to D antigen positive red cells during pregnancy and blood transfusion. Such antibodies are often capable of causing a haemolytic transfusion reaction (HTR) and haemolytic disease of the foetus and newborn (HDFN). Since the introduction of prophylactic anti-D and implementation of evidence based best practice of careful management and monitoring of D negative pregnant women for all the potentially sensitising events that occur during pregnancy, the prevalence of HDFN because of Rh D incompatibility between the mother and baby has declined significantly [90]. In order to prevent Rhesus D negative women who are not previously sensitised from developing alloantibody D, these women are offered prophylactic anti-D during pregnancy under the Routine Antenatal Anti-D Prophylaxis program between 28 and 34 weeks’ gestation. The half-life of the administered anti-D is 12 weeks. The anti-D prevents the mother from being sensitised by micro foetal maternal haemorrhage that can occur as a result of potentially sensitising events that occur during pregnancy. These women should have a fetomaternal haemorrhage testing following any potentially sensitising events that occur after from 20 weeks’ gestation. This test quantifies the amount of foetal red cells that entered the maternal circulation to allow for the administration of adequate dose of anti-D to clear the fotal cells and prevent them from sensitising the mother. Anti-D (125 IU) is required to remove 1 ml of foetal red cells from maternal circulation. RhD alloimmunisation is still a significant cause of foetal and neonatal morbidity and mortality particularly in Nigeria and other developing countries [93, 94, 95] because of absence of evidence-based best practices and non-implementation of Rh D prophylaxis during pregnancy. This often result in a significant number of unfortunate women developing alloantibody D through no fault of theirs but rather as a result of failure in stewardship by the Nigerian government. Also, non-invasive foetal blood group genotyping (DNA) testing of maternal plasma to determine the antigen status of the developing foetus carried by an alloimmunised pregnant women is vital as it provides useful information as to whether a foetus is carrying the group specific antigen and in fact at risk of HDFN. This will help prevent the need for extensive laboratory testing (titration and quantification of antibody every 4 weeks from booking till 28 weeks’ gestation and every 2 weeks from 28 weeks to delivery) and clinical monitoring in antigen negative cases. Molecular testing of maternal plasma for foetal DNA can be performed during the second trimester. DNA probes for the most common antigens associated with HDFN are now available [96]. Knowledge of the molecular basis of the blood group systems has facilitated the development of assays for blood group genotyping. Foetal Rhesus D genotyping can potentially tell at 16 weeks’ gestation through the analysis of amniotic fluid or through maternal plasma the foetal D genotype of the developing foetus. In previously sensitised alloimmunised pregnant women, knowledge of the foetal D antigen status is beneficial to enable obstetricians optimally manage these women [95]. In non-sensitised Rhesus negative pregnant women, the knowledge of the foetal D antigen status is quite important for several reasons; prevent us from exposing the mother to a prophylactic anti-D (a human blood product that even though significantly virally tested for TTIs) she does not need, allow for the optimal utilisation of the product in patients in whom it is indicated and spare the woman the pain of the product being administered intramuscularly. RHD genotyping of foetuses carried by Rh D-negative women using foetal DNA obtained invasively through amniocentesis or chorionic villus sampling used to be critical to the clinical management of these women. Technological advances now allows for accurate determination of foetal Rh D genotype using cell-free foetal DNA from maternal blood, thus overcoming the invasive procedures [97]. Rh D genotyping are based on polymerase chain reaction using non-invasive blood sample from the mum are quite sensitive with low incidence of false positive result [98, 99]. Although there are cases of D-negative genomes possessing fragments of mutated Rh D genes, the most notable of which is the Rh D pseudogene found in Africans. Rh D genotyping tests have been developed to differentiate these alleles and thus enhance the diagnosis in a multi-ethnic population [100].
\nFoetal blood group genotype of a developing foetus can also be determined for Rh C, c, E and Kell (K) using cffDNA from maternal plasma [101]. Many European Union countries have suggested the mass application of foetal genotyping for all foetuses carried by D-negative women. This advocacy is based on clear benefit of conserving anti-D stocks and prevention of unnecessary administration of this human-derived blood product that has associated risk [102, 103]. In Denmark and the Netherlands this evidenced-based best practice of foetal Rh D testing for all non-sensitised D negative pregnant women have been introduced [104]. Also, non-invasive foetal blood group genotyping (DNA) testing of maternal plasma to determine the antigen status of the developing foetus carried by an already alloimmunised pregnant women is vital as it provides useful information as to whether a foetus is carrying the group specific antigen and in fact at risk of haemolytic disease. This will help prevent the need of extensive laboratory (titration and quantification of antibody every 4 weeks till 28 weeks’ gestation and every 2 weeks from 28 weeks to delivery) and clinical monitoring in antigen-negative cases.
\nThe maternal alloantibody D produced as a result of sensitization of the Rh D negative mother to the Rhesus D positive foetal red cells are low molecular weight IgG antibody. This antibody can potentially cross the placenta barrier into the foetal circulation and can destroy the foetal red cells resulting in anaemia, heart failure, hydrops foetalis (fluid retention and swelling) and intrauterine death. In utero the diagnosis of foetal anaemia used to be made by carrying out ultrasound guided foetal blood sampling for analysis of the foetal haemoglobin and haematocrit or amniocentesis-an invasive ultrasound guided procedure with a significant 2% risk of foetal loss associated with entering the amniotic sac and obtaining amniotic fluid which is analysed for product of haemoglobin breakdown. However, non-invasive diagnosis of foetal anaemia can now be made using non-invasive Doppler ultrasound technology by measuring the middle cerebral artery peak systolic velocities (MCA PSV). The foetal anaemia can be managed with intrauterine blood transfusions. Intrauterine transfusion is associated with a number of risks; foetal bradycardia, foetal death, cord haematoma, haemorrhage from the puncture site, miscarriage, preterm labour and vessel spasm. The blood used for such transfusions must meet certain requirements; gamma irradiated red cells to prevent transfusion-associated graft-versus-host disease, haemoglobin S negative, CMV negative and significantly high PCV (0.70–0.85) [105, 106], unit must be C-, D-, E- and K-, leucocyte depleted to less than 1 × 106 leucocytes per unit, less than 5 days old, free from clinically significant irregular blood group antibodies and negative for high-titre anti-A and anti-B haemolysin. If the mother has other alloantibodies apart from D, it is vital that suitable unit negative for the specific antigens to which those maternal alloantibodies are specific are selected. Once the baby is delivered, intensive phototherapy and IV immunoglobulin along with antiglobulin (DAT) test should be carried out. There should also be continuous monitoring of the haemoglobin, haematocrit and bilirubin level. A positive DAT is diagnostic of HDFN and the baby sample should be sent for elution to identify if the antibody coating the foetal red cell is maternal alloantibody. If the bilirubin is not responsive to intensive phototherapy and continues to rise, the associated neonatal anaemia and hyperbilirubinemia can be managed by carrying our exchange blood transfusion (EBT) to prevent bilirubin encephalopathy by removing a significant number of maternal antibodies-coated foetal red cells and excess bilirubin and replacing it with donor red cells. The red cell product used for EBT must meet certain requirements; group O or ABO compatibility (mum and baby), compatible with any maternal antibody, gamma irradiated, collected in saline, adenine, glucose and mannitol (SAGM), fresh less than 5 days old, have high haematocrit (0.5–0.55) to prevent of post-exchange anaemia and polycythaemia and negative for high titre haemolysins. A number of these evidenced-based best practices; facility for intrauterine blood transfusion, facilities for diagnosis of foetal anaemia in utero, maternal alloantibody testing, elution testing, facility for gamma irradiation of blood, CMV testing of donors units, testing of donor units for other clinical significant red cell antigens apart from ABO and Rhesus D, SAGM units and leucodepletion of donor units are often not available in Nigeria and most developing countries. This failure in stewardship by government in these countries limits the delivery of best possible care in the management of HDFN and appropriate transfusion in these patients.
\nHaemolytic Disease of the Foetus and Newborn (HDFN) is the destruction of foetal and newborn red cells by maternally derived alloantibody directed against a red cell antigen often inherited from the father and expressed on foetal cells. These maternal IgG antibodies are low molecular weight and can pass through the placenta barrier into the foetal circulation and bind to the corresponding foetal red cell antigen. The resultant maternal IgG-coated cells interact with foetal macrophages in resulting in their removal by the foetal spleen. This often results in anaemia, erthroblastosis with compensatory erythropoiesis resuming in the foetal liver and spleen, resulting in hepatosplenomegaly and portal hypertension. Maternal antibody screening is undertaken to detect clinically significant antibodies, which might affect the foetus and/or newborn, and to detect antibodies that may cause problems with the provision of compatible blood products for the woman and for the foetus/newborn. Approximately 1% of pregnant women are found to have clinically significant red cell antibodies [107, 108, 109]. The detection of clinically significant antibodies among antenatal women plays an important role in transfusion safety and preventing HDFN. A previous study among antenatal multiparous women in Jammu region of India indicated that the commonly observed alloantibodies were anti-D, anti-E, anti-C and anti-K [110]. Once an antibody has been detected, it is identified by carrying out a panel test. If the antibody specificity is one that has the potential to cause HDFN, the titre/quantification must be carried out periodically. Antibody quantification and titration is performed on patients’ samples, to support the prediction and management of HDFN and ABO mismatched organ transplant. Antibody quantification of anti-D, and anti-c for management of HDFN. Antibody titration in ABO mismatched transplant is carried out to allow clinical assessment of the possibility of carrying out an ABO mismatched transplant, and monitoring of treatment to reduce antibody titre in preparation for ABO mismatched transplant. All clinically significant maternal antibodies detected during antenatal booking or follow up visit must be referred to the reference laboratory for confirmation of specificity, determination of the possibility of the antibody to cause HDFN and for and titre/quantification to allow for the monitoring of antibody. Evidence based best practice in developed countries requires the monitoring of women with red cell antibodies of specificities known to have potential to cause significant HDFN (anti-D, anti-c and anti-K), covering frequency of testing (every 4 weeks from booking until 28 weeks and every 2 weeks there after till delivery), measurement of antibody concentration (by quantification or titration as appropriate), referral to a foetal medicine specialist and follow-up required post-delivery. Antibodies that require quantification include anti-c, anti D, anti c + D, and anti-c + E. The antibodies that require titration include Anti-e, c, E, C+ e, G, CW, Fya, Fyb, K, k, Kpa, Kpb, Jsa, Jsb, M, S, and s. Antibody titration (ABT) is a semi quantitative method used to detect the strength of an alloantibody/antibodies present in the patient’s plasma [111]. Antibody titration is used prenatally to screen for risk of HDFN, haemolytic transfusion reactions and assessment in solid organ or haematopoietic stem cell transplant. To assess risk for HDFN, the titre of the clinically significant alloantibody is performed. When the antibody and the titre strength are identified, ABT is periodically performed throughout pregnancy, whereby plasma samples are compared in parallel with the previously frozen samples to determine if the titre or strength of the antibody is static, decreasing or increasing. Obstetricians can use this information in conjunction with middle cerebral artery Doppler assessment to determine the extent to which the developing infant is affected, the presence of foetal anaemia, decision to carry out intrauterine transfusion as well as decision on whether to deliver the baby earlier to allow for a better and less risky physical management rather than ultrasound-guided in utero management [112]. Colour Doppler ultrasonography a non-invasive technique is currently being used to assess cerebral artery blood flow [113]. Increased cerebral artery blood flow is an indicator of foetal anaemia [114]. Invasive procedures such as amniocentesis or cordocentesis, with subsequent analysis of amniotic fluid and foetal blood sampling obtained by ultrasonography guided procedure are invasive and significantly risky with potential attendant negative effect to the foetus. Accepted titration methodologies include the tube and gel column technology method [115]. A difference of 2 dilutions or a score of 10 is usually an indication of significant change in antibody production. The antibody titre/quantification often rises as a result of re-exposure of the maternal immune system to red cell antigen following the initial sensitising events that occur during pregnancy. Every re-exposure to the initial offending antigen from the foetus to the mother’s immune system often becomes booster doses. These booster doses often result in more antibody production, attendant increase in the titre and quantification. Antibody titration is also commonly used for screening blood products, particularly platelets and plasma as well as group O donor blood intended for transfusion to blood group A, B and AB patients. This is to decrease the risk of haemolytic transfusion reactions due to passive anti-A/anti-B antibodies. The titre of group O products is determined and those with high titers [51, 114] are labelled and used for group O individuals only while those negative for HT haemolysin can be given to A, B and AB individuals [116]. Also, ABT also has a potential role in preventing graft rejection in ABO-incompatible solid organ transplants (heart, liver, and lung) [117] as well as in erythroid engraftment after haematopoietic progenitor cell transplants [118]. Previous report indicates that the performance of antenatal titrations by column agglutination technology (CAT) is at least as sensitive as the performance by the indirect antiglobulin test (IAT) tube method. CAT was found to show greater sensitivity than IAT tube when dealing with anti-c compared to titrating Anti-K. The CAT method also appears to be more sensitive for detecting samples that require referral to the obstetrician [119]. Evidenced-based best practice requires that all pregnant women are tested for the presence of alloantibodies and its titers/quantification during pregnancy as a way of calculating the risk of developing HDFN [120]. Guidelines of the British Committee for standards in Haematology requires that, all pregnant women should be ABO and D antigen typed and screened for presence of alloantibodies at booking and at the 28th week of gestation [121]. Similarly, in the Netherlands, it has been mandatory to screen all pregnant females for presence of alloantibodies [122]. The aim of periodic antibody titration and quantification (every 4 weeks from detection at booking till 28 weeks and every 2 weeks thereafter until delivery) is to determine whether the titre/quantification is static, decreasing or increasing. A static titre/quantification shows that there is no increase in severity over time, a dropping titre/quantification indicate a low risk for HDFN while a rising titre/quantification is an indication of a potentially severe HDFN. For anti-D quantification a level of 4–15 IU indicates a moderate risk while a level > 15 IU indicates a high risk for HDFN. For anti-c a level > 7.5 IU indicates a high risk of HDFN. For anti-K, a titre of 1:32 or greater is indicative of HDFN risk. Generally, a 4-fold increase in the titre of an HDFN-associated alloantibody is an indication of a significant risk for HDFN [68]. In Nigeria and some other African countries alloantibody testing at booking and at 28 weeks gestation is not available, facilities for alloantibody identification and titration/quantification is not available. A number of pregnant women have alloantibodies without knowing and the risk of mortality from HDFN is high. Nigerian and most of these countries can afford to provide the best possible antenatal care for their pregnant population like it obtains in the developed world. However, lack of political will, failure in stewardship and endemic corruption and misappropriation of the people’s resources remains a major challenge to the effective management of the women. African government must rise to the responsibilities and do what is right by implementing evidence-based practice to allow for the effective management of pregnancies associated with clinically significant alloantibodies and its associated HDFN.
\nAlloantibody-D are produced in a woman of child bearing age either as a result of Rhesus D incompatible transfusion (deliberate or erroneous transfusion of D positive donor red cells to Rhesus D negative women) or as a result of prior Rhesus D incompatibility between the mother and the developing foetus. These sensitizations are often as a result of fetomaternal haemorrhage during pregnancy or during delivery. This is often associated with D positive red cells entering into the maternal circulation to sensitise the mother to produce these immune antibody D. This immune D is an IgG class antibody and can potentially cross the placenta in subsequent D positive pregnancies to cause D HDFN. If a Rhesus D negative woman is married to Rh D positive men who are either homozygous or heterozygous for blood group antigen D, there is a 100 and 50% chance respectively of potentially carrying a Rhesus D positive foetus. In such pregnancies the risk of sensitization of the mother during the first pregnancy as a result of fetomaternal haemorrhage (during pregnancy or delivery) of D positive foetal red cell into maternal circulation is high. The recommend that prophylaxis be provided as soon as possible and always within 72 h of the following potentially sensitising event taking place in Rh D negative pregnant women (Amniocentesis, chorionic villus biopsy and cordocentesis, APH, PV bleed during pregnancy, ECV, Abdo trauma (sharp/blunt, open/closed, ectopic pregnancy, evacuation of molar, pregnancy, IUFD, intrauterine intervention during pregnancy (transfusion, surgery, insertion of shunts and laser), miscarriages, TOP, delivery (normal, instrument or C/S) and intraoperative cell salvage) to prevent sensitization and anti-D-related HDFN in subsequent pregnancy. Evidence-based best practice in most developed countries is to prevent this sensitization from taking place by the implementation of the Routine Antenatal Anti-D Prophylaxis (RAADP) programme. This program is alloimmunization prevention where all Rh D negative women are universally offered anti prophylaxis during pregnancy (28 weeks gestation) and following the delivery of a Rhesus positive baby. The implementation of this program has significantly reduced the number of residual alloimmunization from 16% to less than 0.1% [123]. The justification for this implementation is based of scientific evidence that 92% of women who develop an alloantibody-D during pregnancy do so at or after 28 weeks gestation [124, 125].
\nThis implementation has significantly reduced the number of women who are sensitised and by extension the number of D HDFN. However, in countries like Nigeria and some other developing countries where this policy has not been implemented, a significant 14% of unfortunate foetuses are born dead while 50% of those who are born alive suffer from brain injury and neonatal death [126]. This cases of preventable death of Nigerian and African children is a humanitarian emergency that require urgent attention and good will by the Nigerian, African government and people of good will across to globe. Rho(D) immune globulin (RhIG) is a medication that can be given to non-sensitised Rhesus D negative pregnant women to prevent Rh D sensitization. The medication is often administered intramuscularly or intravenously and has a half-life of 12 weeks. Rho(D) immune globulin used for prophylaxis is a human derived fractionated plasma product produced from blood donors who have high levels of anti-D Ig either due to previous sensitization or intentional immunisation of Rh D negative men to produced immune D. This product is significantly virally tested (HBsAg, anti-HIV and HCV RNA) and includes viral inactivation steps in order to further reduce the risk of viral transmission. There is still a small unquantifiable possibility of transmitting prion particularly vCJD or other infectious agents. Product safety data submitted by manufacturers to National Institute of Health and Clinical Excellence technical appraisal guidance 156 (National Institute for Health and Clinical Excellence [127]) indicates a very low rate of adverse event (less than one non-serious per 80,000 doses of anti-D administered) [89]. There is no evidence till date to suggest that prophylactic anti-D administered to Rhesus D negative women during pregnancy is harmful to the foetus. Child birth or delivery is a potential sensitising event that can potentially expose the mother to the Rhesus D positive cells of the baby. Following delivery in these women, the cord blood is tested for ABO, Rh D group and DAT. If the infant is Rhesus D positive, the mother sample taken within 72 h is tested for fetomaternal haemorrhage (flow cytometry of Kleihauer-Betke test). These tests quantify the number of foetal cells that has entered the maternal circulation and thus facilitates the determination of the optimal dosage of prophylactic anti-D to be administered. As a general rule 125iu of anti-D is required to clear 1 ml of foetal cells from maternal circulation. A dose of 300 μg or 1500 IU is often sufficient to prevent alloimmunization after delivery in 99% of cases [128]. If the D-type of a newborn or stillborn is unknown or cannot be determined, a dose of anti-D prophylaxis should be administered. However, if the infant is found Rhesus D negative, prophylaxis will not be required. Evidenced-based best practices in most developed countries as part of their HDFN prevention program recommend the following [92].
\nIn Nigeria and many countries in Africa, these recommendations and best practices are not being implemented. Government in these countries will need to rise up to their responsibilities by implementing these recommendations to prove the sincerity of their resolve to offer their people particularly Rhesus negative women the best possible health care delivery.
\nAnti-D related HDFN often result from the transplacental passage of maternal allo-antibodies directed against foetal red cell antigens inherited from the father affects the foetus or neonate. Majority of the mothers becomes sensitised following small feto-maternal haemorrhages during pregnancy and at delivery of the first Rh D-positive infant. These antibodies can potentially cause HDFN in successive Rh D-positive infants. Implementation of universal access to prophylactic anti-D given during antenatal and post-partum period following the delivery of a Rh D positive baby can help prevent primary Rh D immunisation and risk of HDFN in subsequent pregnancies [129]. It is recommended that routine antenatal anti-D prophylaxis (RAADP) is offered to all non-sensitised pregnant women who are Rh D negative to reduce the risk of sensitization and by extension D-related HDFN [130]. The World Health Organisation (WHO) recommends that antenatal prophylaxis with anti-D immunoglobulin should be given to non-sensitised Rh-negative pregnant women at 28 and 34 weeks of gestation to prevent Rh D alloimmunization. It is estimated that single dose of anti-D can cost around US$ 50 (500 IU) to US$ 87 (1500 IU), depending on the brand and local taxes. Therefore, the cost of antenatal prophylaxis for two 500 IU doses could be as much as US$ 100 per woman. Additional costs will include screening for blood typing in settings where Rh blood tests are not currently performed [131]. However, providing anti-D prophylaxis universally to all Rh D negative non-sensitised pregnant women is not cheap. The cost benefit analysis of preventing sensitization, HDFN and its related physical disabilities, mental retardation and death of affected children supports investing in the implementation of this policy by responsible government who believes that every life count. Routine antenatal anti-D prophylaxis provides a cost effective intervention for preventing HDFN in non-sensitised Rh D-negative pregnant women [132]. Health economic model indicates a significant cost per quality-adjusted life-year (QALY) gained by the implementation of RAADP given to Rh D-negative primigravidae versus no RAADP is between £9000 and £15,000, and for RAADP given to all RhD-negative women rather than to Rh D-negative primigravidae only is between £20,000 and £35,000. It is suggested that a programme of routine prophylaxis would be cost saving if HDFN were eradicated by its implementation [130]. The National Institute for Health and Clinical Excellence reported that when RAADP for all Rh D-negative women was compared with that for primigravidae, the additional cost per incident of sensitisation prevented ranged from £2900 to £8200 depending on the regimen used. The cost per HDFN-associated foetal loss avoided was £42,000–120,000. It does make economic sense for African government to rise to their responsibilities by proving universally anti-D prophylaxis to all non-sensitised Rhesus D negative women. There is also potential to significantly reduce the cost of implementing RAADP by these governments investing on facilities to non-invasive determination of foetal D genotyping for all non-sensitised Rh D negative pregnant women. This will help identify women who are carrying Rhesus D negative mothers who will not require the prophylaxis. Also, because the prevalence of Rh D negative status is significantly lower among Nigerians (6%) [133] compared to the West ≥15% [134], it is likely to cost African countries a lot less to implement universal access to anti-D prophylaxis [135].
\nEvidenced based best practice in management of patients including pregnant women requires that patients are transfused with red cells lacking the group specific antigens to which the recipient alloantibody is specific [136]. This aim of this implementation is to prevent immune mediated destruction of the donor red cells containing the offending antigen [137, 138]. For example, pregnant women who have alloantibody Kell should be given K-negative donor units. The provision of antigen negative blood units for these patients is a special challenge particularly in Nigeria and many other countries in Africa [139]. Although these countries have national blood transfusion services, majority of them are often not fit for purpose. Majority of them test blood donors only for their ABO and Rhesus antigen status [139]. Routine testing of blood donors for other clinically significant red sell antigens are not routinely done. This has a significant implication on haemolytic transfusion reaction and HDFN. In the alloimmuned pregnant women who have low molecular weight immune IgG antibodies, IAT crossmatching should ideally be carried out using donor red cells suspended in low ionic strength saline preferably using highly sensitive column agglutination technique instead of the conventional less sensitive tube methods. Many of these technologies are often not available in most settings in Nigeria and other African countries. Transfusion of antigen positive donor red cells to patient with the group specific antibodies like it potentially happens in Nigeria and some other African countries have significant negative consequences [140]. These antibodies can cause clinically significant haemolytic transfusion reactions, difficulty in cross-matching blood and getting compatible blood in future, cause decrease in RBC survival and thus negate the aim of red cell transfusion of managing anaemia, improving the quality of life and improving the oxygen carrying capacity of the recipient’s blood [141]. Also, there is also the effect of managing donor red cell clearance and the product of red cell breakdown due to haemolysis which often results in multiple organ failure, electrolyte perturbations, coagulopathy and in some severe cases, death [142]. Nigerians and citizens of other African countries deserve the best quality transfusion service like their counterparts in the West. It is the responsibility of African government to work smartly and effectively by avoiding waste and eradicating corruption to ensure that citizens get the best quality health care they deserve.
\nThe accurate detection and quantification of foetal red blood cells (RBCs) in the maternal circulation are necessary for the prevention of Rhesus D alloimmunization among D-negative women because of FMH. It is critical to the administration of adequate amount of anti-D prophylaxis are necessary for the prevention of Rhesus D alloimmunization. As a result of D incompatibility between mother (Rhesus D negative and foetus (D-positive), foetal red cells can enter into maternal circulation and sensitise the mother to produce anti-D alloantibody. These anti-D alloantibodies (small molecular weight IgG antibodies) can pass through the placenta barrier in subsequent D positive pregnancies cause HDFN (haemolysis, foetal anaemia, hydrops foetalis, kernicterus or even death). FMH testing helps obstetrician to determine that a potential sensitising event has taken place and facilitate the administration of adequate amount of prophylactic anti-D (125 IU per 1 ml bleed of foetal red cells into maternal circulation). The widespread use of FMH testing in the evidenced-based provision of adequate immunoprophylaxis with anti-D immunoglobulin has resulted in a significant reduction in the incidence of anti-D related HDFN mortality. Evidence-based best practice implementation of FMH test and provision of immunoprophylaxis with anti-D immunoglobulin in England and Wales has brought about a significant reduction in the number of infants affected with HDFN from affected in 1.2 per 1000 births in 1970 to 0.02 per 1000 births by 1989. There are several methods available for FMH testing (Quantitative and qualitative). Three qualitative methods (micro Du, rosette test, and PEG Du) and two quantitative methods (acid elution and Flow Cytometry) for assessing FMH were evaluated with particular attention given to PEG Du and FC. Of the qualitative techniques, the micro Du test was the least sensitive with 20% false-negative results occurring at 0.5% foetal cells. The PEG Du test was only slightly more sensitive and offered no clinical advantage. The rosette test was the most sensitive, consistently detecting foetal cells at concentrations of 0.25% or greater. Flow Cytometry and acid elution showed similar results, with good correlation obtained between measured and expected quantities of foetal cells (r = 0.99 and 0.96, respectively). One of 26 postpartum samples was positive by all screening techniques; acid elution and FC detected 0.3% concentrations of fetal cells and 0.17% [143, 144]. The rosette screen is a highly sensitive in qualitatively detecting 10 mL of foetal whole blood in the maternal circulation. As the screen is reliant on the presence of the D antigen to distinguish foetal from maternal cells, it cannot be used to detect FMH in D-positive mothers or in D-negative mothers carrying a D-negative fetus. The Kleihauer-Betke acid-elution test, the most widely used confirmatory test for quantifying FMH, relies on the principle that foetal RBCs contain mostly foetal haemoglobin (HbF), which is resistant to acid-elution whereas adult haemoglobin is acid-sensitive. Although the Kleihauer-Betke test is inexpensive and requires no special equipment, it lacks standardisation and precision, and may not be accurate in conditions with elevated F-cells. Flow cytometry is a promising alternative, although its use is limited by equipment and staffing costs. The two well-established confirmatory tests are the Kleihauer-Betke acid-elution assay and flow cytometry. The rosette screen is a highly sensitive FDA approved method to qualitatively detect 10 mL or more of foetal whole blood, or 0.2% foetal cells (volume/volume) in the maternal circulation [143]. The principle is based upon the formation of microscopic foetal D+ aggregates upon incubation of foetal cells with enzyme0-treated group O D-positive indicator RBCs and reagent anti-D serum. The foetal cells must be D-positive and the maternal cells D-negative for the test to be valid. In summary the maternal blood sample is first incubated with anti-D and then washed. The indicator D-positive RBCs are added and the sample is examined under a light microscope. In the presence of anti-D coated foetal D-positive cells, the indicator cells will form aggregates (or rosettes) around the foetal cells. The main limitation of this method is that falsely positive result may occur is the mum has a variant of the D antigen and falsely negative if the foetus or neonate is weak D. Also, mothers that have a positive direct antiglobulin test (DAT) or an autoantibody can produce a false positive result due to the agglutination of the mother’s antibody coated red cells.
\nA positive rosette test is indicative of FMH > 10 mL. In a negative rosette test administration of is 300 μg (1500 IU) of Rh Ig is sufficient to prevent immunisation in 99% of patients. If the rosette test is positive quantification of the FMH by either the Kleihauer-Betke acid elution test or flow cytometry is indicated to determine the optimal dose of prophylactic anti-D immunoglobulin to be administered. The Kleihauer-Betke acid-elution test is an inexpensive method and requires no special equipment and thus can possibly be implemented in developing country like Nigeria and other resource-limited settings. The method is based on the principle that foetal RBCs containing foetal haemoglobin (HbF) to resist acid elution whereas adult haemoglobin does not. When a peripheral smear prepared from a EDTA anticoagulated maternal blood sample is exposed to an acid buffer such as Shepherds stain, haemoglobin in the cytoplasm of maternal red cells are eluted while HbF in the foetal red cells resist acid elution. Subsequent counterstaining with haematoxylin results in red cell containing foetal haemoglobin staining pink while the maternal adult haemoglobin containing red cells appear as ghost. Figure 1 shows a positive Kleihauer-Betke test. To calculate the number of foetal cells in maternal circulation using Kleihauer-Betke test, get a stained thin film on a microscope and replace one of the objectives of the microscope with a graticule (Miller square) (Figure 2). Focus the microscope making sure the graticule is on the top left-hand corner. Select the ×40 lens and count at least 50 fields of the area of the film where the red cells are just touching each other. For each field count all the foetal cells in the large and small square. Count all the maternal cells in the small square. Count fields with at least 25–30 maternal cells. To calculate the total number of maternal cells, add the total number of maternal cells together and multiply by 9. Also add the total number of foetal cells from the 50 fields. The calculation of FMH is done using Mollison’s rule.
\nPositive Kleihauer-Betke test.
Diagram of Miller square (graticule).
Mollison’s rule = 2400 × number of foetal cells ÷ number of maternal cells
\nFor example, if the number of foetal red cells is 20 and the maternal cells is 2000, the FMH = number of maternal cells = 2000 × 9 = 18,000
\n25 × 2400/18,000 = 3.3 mls bleed.
\nCalculation of dose of anti-D. Anti-D administered is calculated by giving 125 IU per ml of FMH. For a 3.3 ml bleed you will have to administer 3.3 × 125 IU = 413 IU of anti-D.
\nThe Kleihauer-Betke method is a labour intensive and subjective method. The accuracy and precision of this method is hampered by lack of standardisation which can potentially lead to slight variations in result (thickness of blood smear, pipetting skill of analyst, pH variations in the buffer used, inter analyst variations). Over- and underestimation of FMH using the Kleihauer-Betke test has been reported [145, 146]. The disadvantages of this method include; laborious to perform, lacks standardisation, is imprecise and may not be accurate in conditions associated with elevated haemoglobin F containing red cells. However, standardisation of the Kleihauer-Betke test can make the result potentially comparable to result from flow cytometry [147]. Haemoglobin F containing red cells are increased in haemoglobinopathies including sickle cell disease and β-thalassemia and hereditary persistence of foetal haemoglobin (HPFH). In 25% of pregnant women, HbF tend to be increased and can cause false positive results [148, 149]. In pregnant women with conditions such as sickle cell disease, thalassaemia and HPFH an alternative method for FMH testing such as flow cytometry should be employed. Despite its limitations, a good correlation has been reported between the Kleihauer-Betke test and flow cytometry for both small and large FMH [150, 151].
\nFlow cytometry involves using a flow cytometer using monoclonal antibodies directed against. Flow cytometric determination of FMH is superior to Kleihauer-Betke test for a number of reasons; cytometric methods can accurately distinguish adult foetal haemoglobin containing red cells from foetal RBCs, flow cytometers rapidly analyses a significantly higher number of cells (≥50,000), thus improving its quantitative accuracy and flow cytometry is automated non-subjective and has greater reproducibility. The only disadvantage is that it requires trained staff to perform test coupled with the fact that it is it is expensive and may not be affordable in low-resource settings.
\nThere is paucity of data on the distribution of clinically significant blood group antigens apart from ABO and Rhesus D among Nigerians. Management of Rhesus D negative pregnancies and pregnancies associated with clinically significant alloantibody is suboptimal. This failure in stewardship by the Nigerian government has a significant implication for Haemolytic Disease of the Foetus and Newborn and haemolytic transfusion reaction. There is need to introduce routine screening of pregnant women in Nigeria for clinically significant red cell antibodies to facilitate the effective management of HDFN as well as prevent HTR by enabling the selection of antigen negative red cells for women who have alloantibodies and require a red cell transfusion.
\nWe recommend that the Nigerian government should implement the following evidence-based best practices (British Committee for Standards in Haematology [152, 153, 154, 155].
That the Nigerian government should fulfil her obligations under goal 3.8 of the Universal Health Coverage initiative and the Sustainable Development goal 3.b which emphasises the need for access to safe, effective, quality and affordable essential medicines for all by implementing universal access to anti-D prophylaxis for previously unsensitized Rhesus D negative pregnant women.
Screen donor units for clinically significant antigen status to facilitate the selection of antigen negative donor units for transfusion to patients with a clinically significant alloantibody.
Routinely screening all blood group O donors whose units are intended for transfusion to non-O recipients for high titre haemolysin.
Anti-D immunoglobulin should be available in cases of potentially sensitising events such as amniocentesis, cordocentesis, antepartum haemorrhage, vaginal bleeding during pregnancy, external cephalic version, abdominal trauma, intrauterine death and stillbirth, in utero therapeutic interventions, miscarriage, and therapeutic termination of pregnancy.
All Rhesus D negative women having a termination of pregnancy (abortion) must be tested for Rhesus D group and those found to be Rhesus D negative must be offered prophylaxis following the procedure.
Routine foetal genotyping using non-invasive testing of maternal sample to identify Rhesus negative pregnant women who are carrying Rhesus negative infants for whom prophylaxis is not indicated.
Facilities for intrauterine transfusion of infants who become anaemic in utero as a result of HDFN and require a red cell transfusion. Facilities to test donor red cells to ensure that they meet the requirements for intrauterine, exchange and top up transfusion.
Facilities for the implementation of alloantibody titration and quantification should be provided for pregnant women with a clinically significant, HDFN causing alloantibody.
There is need for the provision of facilities for fetomaternal haemorrhage testing to facilitate the administration of optimal amount of anti-D prophylaxis following a sensitising event to prevent HDFN.
Knowledge of anti-D prophylaxis and management of women with clinically significant antibodies among Obstetricians, Laboratory of Biomedical Scientist, Midwives, Traditional Birth Attendants, Pharmacists and Nurses in Nigeria and other countries in Africa needs to be improved. This will facilitate quality antenatal and postnatal care offered particularly to Rh-negative pregnant women and those with clinically significant alloantibodies.
That anti-D prophylaxis be provided in Rhesus D negative pregnant pregnancies <12 weeks gestation, following ectopic pregnancy, molar pregnancy, therapeutic termination of pregnancy. FMH haemorrhage (FMH) testing is often not required for sensitising events at <12 weeks gestation.
That for all potentially sensitising events occurring between 12- and 20-weeks’ gestation, prophylaxis should be administered within 72 h of the event without need for FMH testing.
That for potentially sensitising events after 20 weeks gestation, prophylaxis should be administered within 72 h of the event along with testing for FMH. This is to determine if additional dose of anti-D Ig is required for a significant bleed.
That in the event of an intrauterine foetal death (IUFD), where no sample can be obtained from the baby or foetus, an appropriate dose of prophylactic anti-D should be administered to Rhesus D negative, previously non-sensitised women within 72 h of the diagnosis of IUFD, irrespective of the time of subsequent delivery.
That following intra-operative cell salvage (ICS) during Caesarean section in D negative, previously non-sensitised women, and where cord blood group is confirmed as D positive (or unknown), a minimum dose of 1500 IU prophylactic anti-D should be administered following the re-infusion of salvaged red cells. Also, the maternal sample should be taken for estimation of FMH 30–45 min after reinfusion to confirm if a further dose of anti-D Ig is required.
That in cases of therapeutic termination of pregnancy (abortion), whether by surgical or medical methods, and regardless of gestational age, all previously non-sensitised D negative women should receive a dose of prophylactic anti-D within 72 h of having the procedures.
That anti-D prophylaxis should be administered to all cases of ectopic pregnancy in previously non-sensitised, D negative women regardless of the mode of management.
That there is significant potential for sensitisation in cases of molar pregnancy. Anti-D prophylaxis should be administered to all cases of molar pregnancy in previously non-sensitised, D negative women.
That D negative women presenting with continual uterine bleeding between 12- and 20-weeks’ gestation should be offered anti-D prophylaxis at a minimum of 6 weekly intervals.
That under normal circumstances, D negative platelets should be transfused to D negative females or women of child bearing age, who need a platelet transfusion. Occasionally, if the appropriate product is not available or its availability is likely to cause unacceptable delay and harm, it may be necessary to transfuse D positive platelets. In these situations, prophylaxis against possible sensitisation by the D positive red cells contaminating the platelet product should be given. A dose of 250 IU anti-D immunoglobulin is sufficient to cover up to five adult therapeutic doses of D positive platelets given over a 6-weeks period.
IntechOpen aims to guarantee that original material is published while at the same time giving significant freedom to our Authors. We uphold a flexible Copyright Policy, guaranteeing that there is no transfer of copyright to the publisher and Authors retain exclusive copyright to their Work.
',metaTitle:"Publication Agreement - Monograph",metaDescription:"IntechOpen aims to guarantee that original material is published while at the same time giving significant freedom to our authors. For that matter, we uphold a flexible copyright policy meaning that there is no transfer of copyright to the publisher and authors retain exclusive copyright to their work.",metaKeywords:null,canonicalURL:"/page/publication-agreement-monograph",contentRaw:'[{"type":"htmlEditorComponent","content":"When submitting a manuscript, the Author is required to accept the Terms and Conditions set out in our Publication Agreement – Monographs/Compacts as follows:
\\n\\nCORRESPONDING AUTHOR'S GRANT OF RIGHTS
\\n\\nSubject to the following Article, the Author grants to IntechOpen, during the full term of copyright, and any extensions or renewals of that term, the following:
\\n\\nThe foregoing licenses shall survive the expiry or termination of this Publication Agreement for any reason.
\\n\\nThe Author, on his or her own behalf and on behalf of any of the Co-Authors, reserves the following rights in the Work but agrees not to exercise them in such a way as to adversely affect IntechOpen's ability to utilize the full benefit of this Publication Agreement: (i) reprographic rights worldwide, other than those which subsist in the typographical arrangement of the Work as published by IntechOpen; and (ii) public lending rights arising under the Public Lending Right Act 1979, as amended from time to time, and any similar rights arising in any part of the world.
\\n\\nThe Author, and any Co-Author, confirms that they are, and will remain, a member of any applicable licensing and collecting society and any successor to that body responsible for administering royalties for the reprographic reproduction of copyright works.
\\n\\nSubject to the license granted above, copyright in the Work and all versions of it created during IntechOpen's editing process, including all published versions, is retained by the Author and any Co-Authors.
\\n\\nSubject to the license granted above, the Author and Co-Authors retain patent, trademark and other intellectual property rights to the Work.
\\n\\nAll rights granted to IntechOpen in this Article are assignable, sublicensable or otherwise transferrable to third parties without the specific approval of the Author or Co-Authors.
\\n\\nThe Author, on his/her own behalf and on behalf of the Co-Authors, will not assert any rights under the Copyright, Designs and Patents Act 1988 to object to derogatory treatment of the Work as a consequence of IntechOpen's changes to the Work arising from the translation of it, corrections and edits for house style, removal of problematic material and other reasonable edits as determined by IntechOpen.
\\n\\nAUTHOR'S DUTIES
\\n\\nWhen distributing or re-publishing the Work, the Author agrees to credit the Monograph/Compacts as the source of first publication, as well as IntechOpen. The Author guarantees that Co-Authors will also credit the Monograph/Compacts as the source of first publication, as well as IntechOpen, when they are distributing or re-publishing the Work.
\\n\\nThe Author agrees to:
\\n\\nThe Author will be held responsible for the payment of the agreed Open Access Publishing Fee before the completion of the project (Monograph/Compacts publication).
\\n\\nAll payments shall be due 30 days from the date of issue of the invoice. The Author or whoever is paying on behalf of the Author and Co-Authors will bear all banking and similar charges incurred.
\\n\\nThe Author shall obtain in writing all consents necessary for the reproduction of any material in which a third-party right exists, including quotations, photographs and illustrations, in all editions of the Work worldwide for the full term of the above licenses, and shall provide to IntechOpen, at its request, the original copies of such consents for inspection or the photocopies of such consents.
\\n\\nThe Author shall obtain written informed consent for publication from those who might recognize themselves or be identified by others, for example from case reports or photographs.
\\n\\nThe Author shall respect confidentiality during and after the termination of this Agreement. The information contained in all correspondence and documents as part of the publishing activity between IntechOpen and the Author and Co-Authors are confidential and are intended only for the recipients. The contents of any communication may not be disclosed publicly and are not intended for unauthorized use or distribution. Any use, disclosure, copying, or distribution is prohibited and may be unlawful.
\\n\\nAUTHOR'S WARRANTY
\\n\\nThe Author and Co-Authors confirm and warrant that the Work does not and will not breach any applicable law or the rights of any third party and, specifically, that the Work contains no matter that is defamatory or that infringes any literary or proprietary rights, intellectual property rights, or any rights of privacy.
\\n\\nThe Author and Co-Authors confirm that: (i) the Work is their original work and is not copied wholly or substantially from any other work or material or any other source; (ii) the Work has not been formally published in any other peer-reviewed journal or in a book or edited collection, and is not under consideration for any such publication; (iii) Authors and any applicable Co-Authors are qualifying persons under section 154 of the Copyright, Designs and Patents Act 1988; (iv) Authors and any applicable Co-Authors have not assigned, and will not during the term of this Publication Agreement purport to assign, any of the rights granted to IntechOpen under this Publication Agreement; and (v) the rights granted by this Publication Agreement are free from any security interest, option, mortgage, charge or lien.
\\n\\nThe Author and Co-Authors also confirm and warrant that: (i) he/she has the power to enter into this Publication Agreement on his or her own behalf and on behalf of each Co-Author; and (ii) has the necessary rights and/or title in and to the Work to grant IntechOpen, on behalf of themselves and any Co-Author, the rights and licences in this Publication Agreement. If the Work was prepared jointly by the Author and Co-Authors, the Author confirms that: (i) all Co-Authors agree to the submission, license and publication of the Work on the terms of this Publication Agreement; and (ii) the Author has the authority to enter into this biding Publication Agreement on behalf of each Co-Author. The Author shall: (i) ensure each Co-Author complies with all relevant provisions of this Publication Agreement, including those relating to confidentiality, performance and standards, as if a party to this Publication Agreement; and (ii) remain primarily liable for all acts and/or omissions of each Co-Author.
\\n\\nThe Author agrees to indemnify IntechOpen harmless against all liabilities, costs, expenses, damages and losses, as well as all reasonable legal costs and expenses suffered or incurred by IntechOpen arising out of, or in connection with, any breach of the agreed confirmations and warranties. This indemnity shall not apply in a situation in which a claim results from IntechOpen's negligence or willful misconduct.
\\n\\nNothing in this Publication Agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence or any other liability that cannot be excluded or limited by applicable law.
\\n\\nTERMINATION
\\n\\nIntechOpen has the right to terminate this Publication Agreement for quality, program, technical or other reasons with immediate effect, including without limitation (i) if the Author and/or any Co-Author commits a material breach of this Publication Agreement; (ii) if the Author and/or any Co-Author (being a private individual) is the subject of a bankruptcy petition, application or order; or (iii) if the Author and/or any Co-Author (as a corporate entity) commences negotiations with all or any class of its creditors with a view to rescheduling any of its debts, or makes a proposal for, or enters into, any compromise or arrangement with any of its creditors.
\\n\\nIn the event of termination, IntechOpen will notify the Author of the decision in writing.
\\n\\nIntechOpen’s DUTIES AND RIGHTS
\\n\\nUnless prevented from doing so by events beyond its reasonable control, IntechOpen, at its discretion, agrees to publish the Work attributing it to the Author and Co-Authors.
\\n\\nUnless prevented from doing so by events beyond its reasonable control, IntechOpen agrees to provide publishing services which include: managing editing (editorial and publishing process coordination, Author assistance); publishing software technology; language copyediting; typesetting; online publishing; hosting and web management; and abstracting and indexing services.
\\n\\nIntechOpen agrees to offer free online access to readers and use reasonable efforts to promote the Publication to relevant audiences.
\\n\\nIntechOpen is granted the authority to enforce the rights from this Publication Agreement on behalf of the Author and Co-Authors against third parties, for example in cases of plagiarism or copyright infringements. In respect of any such infringement or suspected infringement of the copyright in the Work, IntechOpen shall have absolute discretion in addressing any such infringement that is likely to affect IntechOpen's rights under this Publication Agreement, including issuing and conducting proceedings against the suspected infringer.
\\n\\nIntechOpen has the right to include/use the Author and Co-Authors names and likeness in connection with scientific dissemination, retrieval, archiving, web hosting and promotion and marketing of the Work and has the right to contact the Author and Co-Authors until the Work is publicly available on any platform owned and/or operated by IntechOpen.
\\n\\nMISCELLANEOUS
\\n\\nFurther Assurance: The Author shall ensure that any relevant third party, including any Co-Author, shall execute and deliver whatever further documents or deeds and perform such acts as IntechOpen reasonably requires from time to time for the purpose of giving IntechOpen the full benefit of the provisions of this Publication Agreement.
\\n\\nThird Party Rights: A person who is not a party to this Publication Agreement may not enforce any of its provisions under the Contracts (Rights of Third Parties) Act 1999.
\\n\\nEntire Agreement: This Publication Agreement constitutes the entire agreement between the parties in relation to its subject matter. It replaces all prior agreements, draft agreements, arrangements, collateral warranties, collateral contracts, statements, assurances, representations and undertakings of any nature made by, or on behalf of, the parties, whether oral or written, in relation to that subject matter. Each party acknowledges that in entering into this Publication Agreement it has not relied upon any oral or written statements, collateral or other warranties, assurances, representations or undertakings which were made by or on behalf of the other party in relation to the subject matter of this Publication Agreement at any time before its signature (known as the "Pre-Contractual Statements"), other than those which are set out in this Publication Agreement. Each party hereby waives all rights and remedies which might otherwise be available to it in relation to such Pre-Contractual Statements. Nothing in this clause shall exclude or restrict the liability of either party arising out of any fraudulent pre-contract misrepresentation or concealment.
\\n\\nWaiver: No failure or delay by a party to exercise any right or remedy provided under this Publication Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.
\\n\\nVariation: No variation of this Publication Agreement shall have effect unless it is in writing and signed by the parties, or their duly authorized representatives.
\\n\\nSeverance: If any provision, or part-provision, of this Publication Agreement is, or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to, or deletion of, a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Publication Agreement.
\\n\\nNo partnership: Nothing in this Publication Agreement is intended to, or shall be deemed to, establish or create any partnership or joint venture or the relationship of principal and agent or employer and employee between IntechOpen and the Author or any Co-Author, nor authorize any party to make or enter into any commitments for, or on behalf of, any other party.
\\n\\nGoverning law: This Publication Agreement and any dispute or claim, including non-contractual disputes or claims arising out of, or in connection with it, or its subject matter or formation, shall be governed by and construed in accordance with the law of England and Wales. The parties submit to the exclusive jurisdiction of the English courts to settle any dispute or claim arising out of, or in connection with, this Publication Agreement, including any non-contractual disputes or claims.
\\n\\nPolicy last updated: 2018-09-11
\\n"}]'},components:[{type:"htmlEditorComponent",content:'When submitting a manuscript, the Author is required to accept the Terms and Conditions set out in our Publication Agreement – Monographs/Compacts as follows:
\n\nCORRESPONDING AUTHOR'S GRANT OF RIGHTS
\n\nSubject to the following Article, the Author grants to IntechOpen, during the full term of copyright, and any extensions or renewals of that term, the following:
\n\nThe foregoing licenses shall survive the expiry or termination of this Publication Agreement for any reason.
\n\nThe Author, on his or her own behalf and on behalf of any of the Co-Authors, reserves the following rights in the Work but agrees not to exercise them in such a way as to adversely affect IntechOpen's ability to utilize the full benefit of this Publication Agreement: (i) reprographic rights worldwide, other than those which subsist in the typographical arrangement of the Work as published by IntechOpen; and (ii) public lending rights arising under the Public Lending Right Act 1979, as amended from time to time, and any similar rights arising in any part of the world.
\n\nThe Author, and any Co-Author, confirms that they are, and will remain, a member of any applicable licensing and collecting society and any successor to that body responsible for administering royalties for the reprographic reproduction of copyright works.
\n\nSubject to the license granted above, copyright in the Work and all versions of it created during IntechOpen's editing process, including all published versions, is retained by the Author and any Co-Authors.
\n\nSubject to the license granted above, the Author and Co-Authors retain patent, trademark and other intellectual property rights to the Work.
\n\nAll rights granted to IntechOpen in this Article are assignable, sublicensable or otherwise transferrable to third parties without the specific approval of the Author or Co-Authors.
\n\nThe Author, on his/her own behalf and on behalf of the Co-Authors, will not assert any rights under the Copyright, Designs and Patents Act 1988 to object to derogatory treatment of the Work as a consequence of IntechOpen's changes to the Work arising from the translation of it, corrections and edits for house style, removal of problematic material and other reasonable edits as determined by IntechOpen.
\n\nAUTHOR'S DUTIES
\n\nWhen distributing or re-publishing the Work, the Author agrees to credit the Monograph/Compacts as the source of first publication, as well as IntechOpen. The Author guarantees that Co-Authors will also credit the Monograph/Compacts as the source of first publication, as well as IntechOpen, when they are distributing or re-publishing the Work.
\n\nThe Author agrees to:
\n\nThe Author will be held responsible for the payment of the agreed Open Access Publishing Fee before the completion of the project (Monograph/Compacts publication).
\n\nAll payments shall be due 30 days from the date of issue of the invoice. The Author or whoever is paying on behalf of the Author and Co-Authors will bear all banking and similar charges incurred.
\n\nThe Author shall obtain in writing all consents necessary for the reproduction of any material in which a third-party right exists, including quotations, photographs and illustrations, in all editions of the Work worldwide for the full term of the above licenses, and shall provide to IntechOpen, at its request, the original copies of such consents for inspection or the photocopies of such consents.
\n\nThe Author shall obtain written informed consent for publication from those who might recognize themselves or be identified by others, for example from case reports or photographs.
\n\nThe Author shall respect confidentiality during and after the termination of this Agreement. The information contained in all correspondence and documents as part of the publishing activity between IntechOpen and the Author and Co-Authors are confidential and are intended only for the recipients. The contents of any communication may not be disclosed publicly and are not intended for unauthorized use or distribution. Any use, disclosure, copying, or distribution is prohibited and may be unlawful.
\n\nAUTHOR'S WARRANTY
\n\nThe Author and Co-Authors confirm and warrant that the Work does not and will not breach any applicable law or the rights of any third party and, specifically, that the Work contains no matter that is defamatory or that infringes any literary or proprietary rights, intellectual property rights, or any rights of privacy.
\n\nThe Author and Co-Authors confirm that: (i) the Work is their original work and is not copied wholly or substantially from any other work or material or any other source; (ii) the Work has not been formally published in any other peer-reviewed journal or in a book or edited collection, and is not under consideration for any such publication; (iii) Authors and any applicable Co-Authors are qualifying persons under section 154 of the Copyright, Designs and Patents Act 1988; (iv) Authors and any applicable Co-Authors have not assigned, and will not during the term of this Publication Agreement purport to assign, any of the rights granted to IntechOpen under this Publication Agreement; and (v) the rights granted by this Publication Agreement are free from any security interest, option, mortgage, charge or lien.
\n\nThe Author and Co-Authors also confirm and warrant that: (i) he/she has the power to enter into this Publication Agreement on his or her own behalf and on behalf of each Co-Author; and (ii) has the necessary rights and/or title in and to the Work to grant IntechOpen, on behalf of themselves and any Co-Author, the rights and licences in this Publication Agreement. If the Work was prepared jointly by the Author and Co-Authors, the Author confirms that: (i) all Co-Authors agree to the submission, license and publication of the Work on the terms of this Publication Agreement; and (ii) the Author has the authority to enter into this biding Publication Agreement on behalf of each Co-Author. The Author shall: (i) ensure each Co-Author complies with all relevant provisions of this Publication Agreement, including those relating to confidentiality, performance and standards, as if a party to this Publication Agreement; and (ii) remain primarily liable for all acts and/or omissions of each Co-Author.
\n\nThe Author agrees to indemnify IntechOpen harmless against all liabilities, costs, expenses, damages and losses, as well as all reasonable legal costs and expenses suffered or incurred by IntechOpen arising out of, or in connection with, any breach of the agreed confirmations and warranties. This indemnity shall not apply in a situation in which a claim results from IntechOpen's negligence or willful misconduct.
\n\nNothing in this Publication Agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence or any other liability that cannot be excluded or limited by applicable law.
\n\nTERMINATION
\n\nIntechOpen has the right to terminate this Publication Agreement for quality, program, technical or other reasons with immediate effect, including without limitation (i) if the Author and/or any Co-Author commits a material breach of this Publication Agreement; (ii) if the Author and/or any Co-Author (being a private individual) is the subject of a bankruptcy petition, application or order; or (iii) if the Author and/or any Co-Author (as a corporate entity) commences negotiations with all or any class of its creditors with a view to rescheduling any of its debts, or makes a proposal for, or enters into, any compromise or arrangement with any of its creditors.
\n\nIn the event of termination, IntechOpen will notify the Author of the decision in writing.
\n\nIntechOpen’s DUTIES AND RIGHTS
\n\nUnless prevented from doing so by events beyond its reasonable control, IntechOpen, at its discretion, agrees to publish the Work attributing it to the Author and Co-Authors.
\n\nUnless prevented from doing so by events beyond its reasonable control, IntechOpen agrees to provide publishing services which include: managing editing (editorial and publishing process coordination, Author assistance); publishing software technology; language copyediting; typesetting; online publishing; hosting and web management; and abstracting and indexing services.
\n\nIntechOpen agrees to offer free online access to readers and use reasonable efforts to promote the Publication to relevant audiences.
\n\nIntechOpen is granted the authority to enforce the rights from this Publication Agreement on behalf of the Author and Co-Authors against third parties, for example in cases of plagiarism or copyright infringements. In respect of any such infringement or suspected infringement of the copyright in the Work, IntechOpen shall have absolute discretion in addressing any such infringement that is likely to affect IntechOpen's rights under this Publication Agreement, including issuing and conducting proceedings against the suspected infringer.
\n\nIntechOpen has the right to include/use the Author and Co-Authors names and likeness in connection with scientific dissemination, retrieval, archiving, web hosting and promotion and marketing of the Work and has the right to contact the Author and Co-Authors until the Work is publicly available on any platform owned and/or operated by IntechOpen.
\n\nMISCELLANEOUS
\n\nFurther Assurance: The Author shall ensure that any relevant third party, including any Co-Author, shall execute and deliver whatever further documents or deeds and perform such acts as IntechOpen reasonably requires from time to time for the purpose of giving IntechOpen the full benefit of the provisions of this Publication Agreement.
\n\nThird Party Rights: A person who is not a party to this Publication Agreement may not enforce any of its provisions under the Contracts (Rights of Third Parties) Act 1999.
\n\nEntire Agreement: This Publication Agreement constitutes the entire agreement between the parties in relation to its subject matter. It replaces all prior agreements, draft agreements, arrangements, collateral warranties, collateral contracts, statements, assurances, representations and undertakings of any nature made by, or on behalf of, the parties, whether oral or written, in relation to that subject matter. Each party acknowledges that in entering into this Publication Agreement it has not relied upon any oral or written statements, collateral or other warranties, assurances, representations or undertakings which were made by or on behalf of the other party in relation to the subject matter of this Publication Agreement at any time before its signature (known as the "Pre-Contractual Statements"), other than those which are set out in this Publication Agreement. Each party hereby waives all rights and remedies which might otherwise be available to it in relation to such Pre-Contractual Statements. Nothing in this clause shall exclude or restrict the liability of either party arising out of any fraudulent pre-contract misrepresentation or concealment.
\n\nWaiver: No failure or delay by a party to exercise any right or remedy provided under this Publication Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.
\n\nVariation: No variation of this Publication Agreement shall have effect unless it is in writing and signed by the parties, or their duly authorized representatives.
\n\nSeverance: If any provision, or part-provision, of this Publication Agreement is, or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to, or deletion of, a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Publication Agreement.
\n\nNo partnership: Nothing in this Publication Agreement is intended to, or shall be deemed to, establish or create any partnership or joint venture or the relationship of principal and agent or employer and employee between IntechOpen and the Author or any Co-Author, nor authorize any party to make or enter into any commitments for, or on behalf of, any other party.
\n\nGoverning law: This Publication Agreement and any dispute or claim, including non-contractual disputes or claims arising out of, or in connection with it, or its subject matter or formation, shall be governed by and construed in accordance with the law of England and Wales. The parties submit to the exclusive jurisdiction of the English courts to settle any dispute or claim arising out of, or in connection with, this Publication Agreement, including any non-contractual disputes or claims.
\n\nPolicy last updated: 2018-09-11
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"58592",title:"Dr.",name:"Arun",middleName:null,surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/58592/images/1664_n.jpg",biography:"Arun K. Shanker is serving as a Principal Scientist (Plant Physiology) with the Indian Council of Agricultural Research (ICAR) at the Central Research Institute for Dryland Agriculture in Hyderabad, India. He is working with the ICAR as a full time researcher since 1993 and has since earned his Advanced degree in Crop Physiology while in service. He has been awarded the prestigious Member of the Royal Society of Chemistry (MRSC), by the Royal Society of Chemistry, London in 2015. Presently he is working on systems biology approach to study the mechanism of abiotic stress tolerance in crops. His main focus now is to unravel the mechanism of drought and heat stress response in plants to tackle climate change related threats in agriculture.",institutionString:null,institution:{name:"Indian Council of Agricultural Research",country:{name:"India"}}},{id:"4782",title:"Prof.",name:"Bishnu",middleName:"P",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/4782/images/system/4782.jpg",biography:"Bishnu P. Pal is Professor of Physics at Mahindra École\nCentrale Hyderabad India since July 1st 2014 after retirement\nas Professor of Physics from IIT Delhi; Ph.D.’1975 from IIT\nDelhi; Fellow of OSA and SPIE; Senior Member IEEE;\nHonorary Foreign Member Royal Norwegian Society for\nScience and Arts; Member OSA Board of Directors (2009-\n11); Distinguished Lecturer IEEE Photonics Society (2005-\n07).",institutionString:null,institution:{name:"Indian Institute of Technology Delhi",country:{name:"India"}}},{id:"69653",title:"Dr.",name:"Chusak",middleName:null,surname:"Limsakul",slug:"chusak-limsakul",fullName:"Chusak Limsakul",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Prince of Songkla University",country:{name:"Thailand"}}},{id:"75563",title:"Dr.",name:"Farzana Khan",middleName:null,surname:"Perveen",slug:"farzana-khan-perveen",fullName:"Farzana Khan Perveen",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/75563/images/system/75563.png",biography:"Dr Farzana Khan Perveen (FLS; Gold-Medallist) obtained her BSc (Hons) and MSc (Zoology: Entomology) from the University of Karachi, MAS (Monbush-Scholar; Agriculture: Agronomy) and from the Nagoya University, Japan, and PhD (Research and Course-works from the Nagoya University; Toxicology) degree from the University of Karachi. She is Founder/Chairperson of the Department of Zoology (DOZ) and Ex-Controller of Examinations at Shaheed Benazir Bhutto University (SBBU) and Ex-Founder/ Ex-Chairperson of DOZ, Hazara University and Kohat University of Science & Technology. \nShe is the author of 150 high impact research papers, 135 abstracts, 4 authored books and 8 chapters. She is the editor of 5 books and she supervised BS(4), MSc(50), MPhil(40), and Ph.D. (1) students. She has organized and participated in numerous international and national conferences and received multiple awards and fellowships. She is a member of research societies, editorial boards of Journals, and World-Commission on Protected Areas, International Union for Conservation of Nature. Her fields of interest are Entomology, Toxicology, Forensic Entomology, and Zoology.",institutionString:"Shaheed Benazir Bhutto University",institution:{name:"Shaheed Benazir Bhutto University",country:{name:"Pakistan"}}},{id:"23804",title:"Dr.",name:"Hamzah",middleName:null,surname:"Arof",slug:"hamzah-arof",fullName:"Hamzah Arof",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/23804/images/5492_n.jpg",biography:"Hamzah Arof received his BSc from Michigan State University, and PhD from the University of Wales. Both degrees were in electrical engineering. His current research interests include signal processing and photonics. Currently he is affiliated with the Department of Electrical Engineering, University of Malaya, Malaysia.",institutionString:null,institution:{name:"University of Malaya",country:{name:"Malaysia"}}},{id:"41989",title:"Prof.",name:"He",middleName:null,surname:"Tian",slug:"he-tian",fullName:"He Tian",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"East China University of Science and Technology",country:{name:"China"}}},{id:"33351",title:null,name:"Hendra",middleName:null,surname:"Hermawan",slug:"hendra-hermawan",fullName:"Hendra Hermawan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/33351/images/168_n.jpg",biography:null,institutionString:null,institution:{name:"Institut Teknologi Bandung",country:{name:"Indonesia"}}},{id:"11981",title:"Prof.",name:"Hiroshi",middleName:null,surname:"Ishiguro",slug:"hiroshi-ishiguro",fullName:"Hiroshi Ishiguro",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Osaka University",country:{name:"Japan"}}},{id:"45747",title:"Dr.",name:"Hsin-I",middleName:null,surname:"Chang",slug:"hsin-i-chang",fullName:"Hsin-I Chang",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/no_image.jpg",biography:null,institutionString:null,institution:{name:"National Chiayi University",country:{name:"Taiwan"}}},{id:"61581",title:"Dr.",name:"Joy Rizki Pangestu",middleName:null,surname:"Djuansjah",slug:"joy-rizki-pangestu-djuansjah",fullName:"Joy Rizki Pangestu Djuansjah",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/61581/images/237_n.jpg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",country:{name:"Malaysia"}}},{id:"94249",title:"Prof.",name:"Junji",middleName:null,surname:"Kido",slug:"junji-kido",fullName:"Junji Kido",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Yamagata University",country:{name:"Japan"}}},{id:"12009",title:"Dr.",name:"Ki Young",middleName:null,surname:"Kim",slug:"ki-young-kim",fullName:"Ki Young Kim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12009/images/system/12009.jpg",biography:"Http://m80.knu.ac.kr/~doors",institutionString:null,institution:{name:"National Cheng Kung University",country:{name:"Taiwan"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5699},{group:"region",caption:"Middle and South America",value:2,count:5172},{group:"region",caption:"Africa",value:3,count:1689},{group:"region",caption:"Asia",value:4,count:10244},{group:"region",caption:"Australia and Oceania",value:5,count:888},{group:"region",caption:"Europe",value:6,count:15650}],offset:12,limit:12,total:10244},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"dateEndThirdStepPublish",topicId:"5"},books:[{type:"book",id:"10358",title:"Silage - Recent Advances and New Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"1e33f63e9311af352daf51d49f0a3aef",slug:null,bookSignature:"Dr. Juliana Oliveira and Dr. Edson Mauro Santos",coverURL:"https://cdn.intechopen.com/books/images_new/10358.jpg",editedByType:null,editors:[{id:"180036",title:"Dr.",name:"Juliana",surname:"Oliveira",slug:"juliana-oliveira",fullName:"Juliana Oliveira"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10238",title:"Food Packaging",subtitle:null,isOpenForSubmission:!0,hash:"891ee7ffd87b72cf155fcdf9c8ae5d1a",slug:null,bookSignature:"Dr. Norizah Mhd Sarbon",coverURL:"https://cdn.intechopen.com/books/images_new/10238.jpg",editedByType:null,editors:[{id:"246000",title:"Dr.",name:"Norizah",surname:"Mhd Sarbon",slug:"norizah-mhd-sarbon",fullName:"Norizah Mhd Sarbon"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9706",title:"Goat Science - Environment, Health and Economy",subtitle:null,isOpenForSubmission:!0,hash:"7e5d45badb49806d949ad1475e3a0ef0",slug:null,bookSignature:"Prof. Sándor Kukovics",coverURL:"https://cdn.intechopen.com/books/images_new/9706.jpg",editedByType:null,editors:[{id:"25894",title:"Prof.",name:"Sándor",surname:"Kukovics",slug:"sandor-kukovics",fullName:"Sándor Kukovics"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9710",title:"Olive Oil - New Perspectives and Applications",subtitle:null,isOpenForSubmission:!0,hash:"2f673efc0d0213f2d937fc89e65a24df",slug:null,bookSignature:"Dr. Muhammad Akram",coverURL:"https://cdn.intechopen.com/books/images_new/9710.jpg",editedByType:null,editors:[{id:"215436",title:"Dr.",name:"Muhammad",surname:"Akram",slug:"muhammad-akram",fullName:"Muhammad Akram"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9715",title:"Botany - Recent Advances and Applications",subtitle:null,isOpenForSubmission:!0,hash:"3e59225e9e029129a60fe724004b8d24",slug:null,bookSignature:"Prof. Bimal Kumar Ghimire",coverURL:"https://cdn.intechopen.com/books/images_new/9715.jpg",editedByType:null,editors:[{id:"94560",title:"Prof.",name:"Bimal Kumar",surname:"Ghimire",slug:"bimal-kumar-ghimire",fullName:"Bimal Kumar Ghimire"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9651",title:"Cereal Grains",subtitle:null,isOpenForSubmission:!0,hash:"918540a77975243ee748770aea1f4af2",slug:null,bookSignature:"Dr. Aakash Goyal",coverURL:"https://cdn.intechopen.com/books/images_new/9651.jpg",editedByType:null,editors:[{id:"97604",title:"Dr.",name:"Aakash",surname:"Goyal",slug:"aakash-goyal",fullName:"Aakash Goyal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10236",title:"Plasmodium Species and Drug Resistance",subtitle:null,isOpenForSubmission:!0,hash:"964a389525d1147af3e527c056ac1a73",slug:null,bookSignature:"Dr. Rajeev K. Tyagi",coverURL:"https://cdn.intechopen.com/books/images_new/10236.jpg",editedByType:null,editors:[{id:"269120",title:"Dr.",name:"Rajeev K.",surname:"Tyagi",slug:"rajeev-k.-tyagi",fullName:"Rajeev K. Tyagi"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8950",title:"Birds - Challenges and Opportunities for Business, Conservation and Research",subtitle:null,isOpenForSubmission:!0,hash:"404a05af45e47e43871f4a0b1bedc6fd",slug:null,bookSignature:"Dr. Heimo Juhani Mikkola",coverURL:"https://cdn.intechopen.com/books/images_new/8950.jpg",editedByType:null,editors:[{id:"144330",title:"Dr.",name:"Heimo",surname:"Mikkola",slug:"heimo-mikkola",fullName:"Heimo Mikkola"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9662",title:"Vegetation Index and Dynamics",subtitle:null,isOpenForSubmission:!0,hash:"0abf2a59ee63fc1ba4fb64d77c9b1be7",slug:null,bookSignature:"Dr. Eusebio Cano Carmona, Dr. Ricardo Quinto Canas, Dr. Ana Cano Ortiz and Dr. Carmelo Maria Musarella",coverURL:"https://cdn.intechopen.com/books/images_new/9662.jpg",editedByType:null,editors:[{id:"87846",title:"Dr.",name:"Eusebio",surname:"Cano Carmona",slug:"eusebio-cano-carmona",fullName:"Eusebio Cano Carmona"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:9},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:16},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:6},{group:"topic",caption:"Computer and Information Science",value:9,count:10},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:4},{group:"topic",caption:"Engineering",value:11,count:15},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:4},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:56},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:9},popularBooks:{featuredBooks:[{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5143},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9279",title:"Concepts, Applications and Emerging Opportunities in Industrial Engineering",subtitle:null,isOpenForSubmission:!1,hash:"9bfa87f9b627a5468b7c1e30b0eea07a",slug:"concepts-applications-and-emerging-opportunities-in-industrial-engineering",bookSignature:"Gary Moynihan",coverURL:"https://cdn.intechopen.com/books/images_new/9279.jpg",editors:[{id:"16974",title:"Dr.",name:"Gary",middleName:null,surname:"Moynihan",slug:"gary-moynihan",fullName:"Gary Moynihan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7807",title:"A Closer Look at Organizational Culture in Action",subtitle:null,isOpenForSubmission:!1,hash:"05c608b9271cc2bc711f4b28748b247b",slug:"a-closer-look-at-organizational-culture-in-action",bookSignature:"Süleyman Davut Göker",coverURL:"https://cdn.intechopen.com/books/images_new/7807.jpg",editors:[{id:"190035",title:"Associate Prof.",name:"Süleyman Davut",middleName:null,surname:"Göker",slug:"suleyman-davut-goker",fullName:"Süleyman Davut Göker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editedByType:"Edited by",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editedByType:"Edited by",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9569",title:"Methods in Molecular Medicine",subtitle:null,isOpenForSubmission:!1,hash:"691d3f3c4ac25a8093414e9b270d2843",slug:"methods-in-molecular-medicine",bookSignature:"Yusuf Tutar",coverURL:"https://cdn.intechopen.com/books/images_new/9569.jpg",editedByType:"Edited by",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editedByType:"Edited by",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editedByType:"Edited by",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8063",title:"Food Security in Africa",subtitle:null,isOpenForSubmission:!1,hash:"8cbf3d662b104d19db2efc9d59249efc",slug:"food-security-in-africa",bookSignature:"Barakat Mahmoud",coverURL:"https://cdn.intechopen.com/books/images_new/8063.jpg",editedByType:"Edited by",editors:[{id:"92016",title:"Dr.",name:"Barakat",middleName:null,surname:"Mahmoud",slug:"barakat-mahmoud",fullName:"Barakat Mahmoud"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10118",title:"Plant Stress Physiology",subtitle:null,isOpenForSubmission:!1,hash:"c68b09d2d2634fc719ae3b9a64a27839",slug:"plant-stress-physiology",bookSignature:"Akbar Hossain",coverURL:"https://cdn.intechopen.com/books/images_new/10118.jpg",editedByType:"Edited by",editors:[{id:"280755",title:"Dr.",name:"Akbar",middleName:null,surname:"Hossain",slug:"akbar-hossain",fullName:"Akbar Hossain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editedByType:"Edited by",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editedByType:"Edited by",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editedByType:"Edited by",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"193",title:"Pathology",slug:"medicine-pathology",parent:{title:"Medicine",slug:"medicine"},numberOfBooks:12,numberOfAuthorsAndEditors:366,numberOfWosCitations:78,numberOfCrossrefCitations:80,numberOfDimensionsCitations:176,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"medicine-pathology",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9135",title:"Rare Diseases",subtitle:null,isOpenForSubmission:!1,hash:"607a44edc1c494df4d5d126af71ca89c",slug:"rare-diseases",bookSignature:"Zhan He Wu",coverURL:"https://cdn.intechopen.com/books/images_new/9135.jpg",editedByType:"Edited by",editors:[{id:"226446",title:"Dr.",name:"Zhan He",middleName:null,surname:"Wu",slug:"zhan-he-wu",fullName:"Zhan He Wu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6790",title:"Fluid and Electrolyte Disorders",subtitle:null,isOpenForSubmission:!1,hash:"5f74d43da90463b17a26bbf2fb7a09ed",slug:"fluid-and-electrolyte-disorders",bookSignature:"Usman Mahmood",coverURL:"https://cdn.intechopen.com/books/images_new/6790.jpg",editedByType:"Edited by",editors:[{id:"183337",title:"Dr.",name:"Usman",middleName:null,surname:"Mahmood",slug:"usman-mahmood",fullName:"Usman Mahmood"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7009",title:"Hypoxia and Anoxia",subtitle:null,isOpenForSubmission:!1,hash:"80148bd84e86e5fe1c7527637e8e3be8",slug:"hypoxia-and-anoxia",bookSignature:"Kusal K. Das and Mallanagouda Shivanagouda Biradar",coverURL:"https://cdn.intechopen.com/books/images_new/7009.jpg",editedByType:"Edited by",editors:[{id:"187859",title:"Prof.",name:"Kusal",middleName:"K.",surname:"Das",slug:"kusal-das",fullName:"Kusal Das"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6297",title:"Histopathology",subtitle:"An Update",isOpenForSubmission:!1,hash:"395c889b2d2cc4f452fe7e1ad8226fe4",slug:"histopathology-an-update",bookSignature:"Supriya Srivastava",coverURL:"https://cdn.intechopen.com/books/images_new/6297.jpg",editedByType:"Edited by",editors:[{id:"85273",title:"Dr.",name:"Supriya",middleName:null,surname:"Srivastava",slug:"supriya-srivastava",fullName:"Supriya Srivastava"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5906",title:"Pathophysiology",subtitle:"Altered Physiological States",isOpenForSubmission:!1,hash:"b277409ee570d9c47798ff5b42638603",slug:"pathophysiology-altered-physiological-states",bookSignature:"David C. Gaze",coverURL:"https://cdn.intechopen.com/books/images_new/5906.jpg",editedByType:"Edited by",editors:[{id:"71983",title:"Dr.",name:"David C.",middleName:null,surname:"Gaze",slug:"david-c.-gaze",fullName:"David C. Gaze"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6025",title:"Temporomandibular Joint Pathology",subtitle:"Current Approaches and Understanding",isOpenForSubmission:!1,hash:"6663d492aea23855b9fdcf753089981e",slug:"temporomandibular-joint-pathology-current-approaches-and-understanding",bookSignature:"Yusuf Emes, Buket Aybar and Gühan Dergin",coverURL:"https://cdn.intechopen.com/books/images_new/6025.jpg",editedByType:"Edited by",editors:[{id:"178414",title:"Prof.",name:"Yusuf",middleName:null,surname:"Emes",slug:"yusuf-emes",fullName:"Yusuf Emes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5955",title:"Chronic Kidney Disease",subtitle:"from Pathophysiology to Clinical Improvements",isOpenForSubmission:!1,hash:"b371e3b8f0d78aa871934011fa0860c7",slug:"chronic-kidney-disease-from-pathophysiology-to-clinical-improvements",bookSignature:"Thomas Rath",coverURL:"https://cdn.intechopen.com/books/images_new/5955.jpg",editedByType:"Edited by",editors:[{id:"67436",title:"Dr.",name:"Thomas",middleName:null,surname:"Rath",slug:"thomas-rath",fullName:"Thomas Rath"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2619",title:"Histopathology",subtitle:"Reviews and Recent Advances",isOpenForSubmission:!1,hash:"fe380d20a204de277654d4d89459cfc4",slug:"histopathology-reviews-and-recent-advances",bookSignature:"Enrique Poblet Martinez",coverURL:"https://cdn.intechopen.com/books/images_new/2619.jpg",editedByType:"Edited by",editors:[{id:"157748",title:"Dr.",name:"Enrique",middleName:null,surname:"Poblet",slug:"enrique-poblet",fullName:"Enrique Poblet"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"788",title:"Topics in Renal Biopsy and Pathology",subtitle:null,isOpenForSubmission:!1,hash:"ff37da307f4471516e16d5801fbb9164",slug:"topics-in-renal-biopsy-and-pathology",bookSignature:"Muhammed Mubarak and Javed I. Kazi",coverURL:"https://cdn.intechopen.com/books/images_new/788.jpg",editedByType:"Edited by",editors:[{id:"119854",title:"Dr.",name:"Muhammed",middleName:null,surname:"Mubarak",slug:"muhammed-mubarak",fullName:"Muhammed Mubarak"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"733",title:"Muscle Biopsy",subtitle:null,isOpenForSubmission:!1,hash:"6d793e898675e9191a913e63cfebab37",slug:"muscle-biopsy",bookSignature:"Challa Sundaram",coverURL:"https://cdn.intechopen.com/books/images_new/733.jpg",editedByType:"Edited by",editors:[{id:"75812",title:"Dr.",name:"Challa",middleName:null,surname:"Sundaram",slug:"challa-sundaram",fullName:"Challa Sundaram"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"985",title:"Prostate Biopsy",subtitle:null,isOpenForSubmission:!1,hash:"2d821ee10598f9f1022eda0fe588f035",slug:"prostate-biopsy",bookSignature:"Nabil Kaddis Bissada",coverURL:"https://cdn.intechopen.com/books/images_new/985.jpg",editedByType:"Edited by",editors:[{id:"92564",title:"Dr.",name:"Nabil K.",middleName:null,surname:"Bissada",slug:"nabil-k.-bissada",fullName:"Nabil K. Bissada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"287",title:"Liver Biopsy",subtitle:null,isOpenForSubmission:!1,hash:"9856c3e2c382494e27f34c5264f50fd4",slug:"liver-biopsy",bookSignature:"Hirokazu Takahashi",coverURL:"https://cdn.intechopen.com/books/images_new/287.jpg",editedByType:"Edited by",editors:[{id:"40534",title:"Dr",name:"Hirokazu",middleName:null,surname:"Takahashi",slug:"hirokazu-takahashi",fullName:"Hirokazu Takahashi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:12,mostCitedChapters:[{id:"18773",doi:"10.5772/20110",title:"Ishak versus METAVIR: Terminology, Convertibility and Correlation with Laboratory Changes in Chronic Hepatitis C",slug:"ishak-versus-metavir-terminology-convertibility-and-correlation-with-laboratory-changes-in-chronic-h",totalDownloads:33121,totalCrossrefCites:9,totalDimensionsCites:18,book:{slug:"liver-biopsy",title:"Liver Biopsy",fullTitle:"Liver Biopsy"},signatures:"Gamal Shiha and Khaled Zalata",authors:[{id:"37453",title:"Prof.",name:"Gamal",middleName:null,surname:"Shiha",slug:"gamal-shiha",fullName:"Gamal Shiha"}]},{id:"25595",doi:"10.5772/33534",title:"Generation and Use of Cultured Human Primary Myotubes",slug:"generation-and-use-of-cultured-human-primary-myotubes",totalDownloads:2962,totalCrossrefCites:5,totalDimensionsCites:9,book:{slug:"muscle-biopsy",title:"Muscle Biopsy",fullTitle:"Muscle Biopsy"},signatures:"Lauren Cornall, Deanne Hryciw, Michael Mathai and Andrew McAinch",authors:[{id:"96027",title:"Dr.",name:"Andrew",middleName:null,surname:"McAinch",slug:"andrew-mcainch",fullName:"Andrew McAinch"}]},{id:"18781",doi:"10.5772/19224",title:"Transient Elastography for Assessment of Non-Alcoholic Fatty Liver Disease",slug:"transient-elastography-for-assessment-of-non-alcoholic-fatty-liver-disease",totalDownloads:2561,totalCrossrefCites:0,totalDimensionsCites:9,book:{slug:"liver-biopsy",title:"Liver Biopsy",fullTitle:"Liver Biopsy"},signatures:"Ludovico Abenavoli",authors:[{id:"34117",title:"Prof.",name:"Ludovico",middleName:null,surname:"Abenavoli",slug:"ludovico-abenavoli",fullName:"Ludovico Abenavoli"}]}],mostDownloadedChaptersLast30Days:[{id:"59286",title:"Surgical Approaches to the Temporomandibular Joint",slug:"surgical-approaches-to-the-temporomandibular-joint",totalDownloads:5380,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"temporomandibular-joint-pathology-current-approaches-and-understanding",title:"Temporomandibular Joint Pathology",fullTitle:"Temporomandibular Joint Pathology - Current Approaches and Understanding"},signatures:"Mohammad Esmaeelinejad and Maryam Sohrabi",authors:[{id:"172188",title:"Dr.",name:"Mohammad",middleName:null,surname:"Esmaeelinejad",slug:"mohammad-esmaeelinejad",fullName:"Mohammad Esmaeelinejad"},{id:"240723",title:"Dr.",name:"Maryam",middleName:null,surname:"Sohrabi",slug:"maryam-sohrabi",fullName:"Maryam Sohrabi"}]},{id:"58358",title:"Internal Derangements of the Temporomandibular Joint: Diagnosis and Management",slug:"internal-derangements-of-the-temporomandibular-joint-diagnosis-and-management",totalDownloads:2078,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"temporomandibular-joint-pathology-current-approaches-and-understanding",title:"Temporomandibular Joint Pathology",fullTitle:"Temporomandibular Joint Pathology - Current Approaches and Understanding"},signatures:"Ufuk Tatli and Vladimir Machon",authors:[{id:"203864",title:"Associate Prof.",name:"Ufuk",middleName:null,surname:"Tatli",slug:"ufuk-tatli",fullName:"Ufuk Tatli"},{id:"204401",title:"Dr.",name:"Vladimir",middleName:null,surname:"Machon",slug:"vladimir-machon",fullName:"Vladimir Machon"}]},{id:"41363",title:"Molecular Histopathology",slug:"molecular-histopathology",totalDownloads:6057,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"histopathology-reviews-and-recent-advances",title:"Histopathology",fullTitle:"Histopathology - Reviews and Recent Advances"},signatures:"Hussein A. Kaoud",authors:[{id:"265070",title:"Dr.",name:"Hussein Abdelhay",middleName:null,surname:"Essayed Kaoud",slug:"hussein-abdelhay-essayed-kaoud",fullName:"Hussein Abdelhay Essayed Kaoud"}]},{id:"58425",title:"Inflammation and Chronic Kidney Disease: Current Approaches and Recent Advances",slug:"inflammation-and-chronic-kidney-disease-current-approaches-and-recent-advances",totalDownloads:1518,totalCrossrefCites:0,totalDimensionsCites:2,book:{slug:"chronic-kidney-disease-from-pathophysiology-to-clinical-improvements",title:"Chronic Kidney Disease",fullTitle:"Chronic Kidney Disease - from Pathophysiology to Clinical Improvements"},signatures:"Simona Mihai, Elena Codrici, Ionela Daniela Popescu, Ana-Maria\nEnciu, Laura Georgiana Necula, Gabriela Anton and Cristiana\nTanase",authors:[{id:"76152",title:"Dr.",name:"Cristiana",middleName:null,surname:"Pistol-Tanase",slug:"cristiana-pistol-tanase",fullName:"Cristiana Pistol-Tanase"},{id:"80114",title:"Dr.",name:"Gabriela",middleName:null,surname:"Anton",slug:"gabriela-anton",fullName:"Gabriela Anton"},{id:"215418",title:"Dr.",name:"Ana-Maria",middleName:null,surname:"Enciu",slug:"ana-maria-enciu",fullName:"Ana-Maria Enciu"},{id:"216223",title:"Dr.",name:"Elena",middleName:null,surname:"Codrici",slug:"elena-codrici",fullName:"Elena Codrici"},{id:"216226",title:"Dr.",name:"Ionela Daniela",middleName:null,surname:"Popescu",slug:"ionela-daniela-popescu",fullName:"Ionela Daniela Popescu"},{id:"216227",title:"Dr.",name:"Simona",middleName:null,surname:"Mihai",slug:"simona-mihai",fullName:"Simona Mihai"},{id:"223988",title:"Dr.",name:"Laura Georgiana",middleName:null,surname:"Necula",slug:"laura-georgiana-necula",fullName:"Laura Georgiana Necula"}]},{id:"62184",title:"Hyponatremia and Psychotropic Drugs",slug:"hyponatremia-and-psychotropic-drugs",totalDownloads:1022,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"fluid-and-electrolyte-disorders",title:"Fluid and Electrolyte Disorders",fullTitle:"Fluid and Electrolyte Disorders"},signatures:"Mireia Martínez Cortés and Pedro Gurillo Muñoz",authors:null},{id:"41355",title:"Ossifying Fibromas of the Craniofacial Skeleton",slug:"ossifying-fibromas-of-the-craniofacial-skeleton",totalDownloads:3191,totalCrossrefCites:5,totalDimensionsCites:6,book:{slug:"histopathology-reviews-and-recent-advances",title:"Histopathology",fullTitle:"Histopathology - Reviews and Recent Advances"},signatures:"Bruno Carvalho, Manuel Pontes, Helena Garcia, Paulo Linhares and Rui Vaz",authors:[{id:"140061",title:"Dr.",name:"Bruno",middleName:null,surname:"Carvalho",slug:"bruno-carvalho",fullName:"Bruno Carvalho"},{id:"142266",title:"Dr.",name:"Manuel",middleName:null,surname:"Pontes",slug:"manuel-pontes",fullName:"Manuel Pontes"},{id:"142267",title:"Dr.",name:"Paulo",middleName:null,surname:"Linhares",slug:"paulo-linhares",fullName:"Paulo Linhares"},{id:"142268",title:"Prof.",name:"Rui",middleName:null,surname:"Vaz",slug:"rui-vaz",fullName:"Rui Vaz"},{id:"142958",title:"Dr.",name:"Helena",middleName:null,surname:"Garcia",slug:"helena-garcia",fullName:"Helena Garcia"}]},{id:"62764",title:"Thyroid Nodules in Diagnostic Pathology: From Classic Concepts to Innovations",slug:"thyroid-nodules-in-diagnostic-pathology-from-classic-concepts-to-innovations",totalDownloads:850,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"histopathology-an-update",title:"Histopathology",fullTitle:"Histopathology - An Update"},signatures:"Ilze Fridrihsone, Ilze Strumfa, Boriss Strumfs, Andrejs Vanags, Dainis\nBalodis, Arvids Jakovlevs, Arnis Abolins and Janis Gardovskis",authors:[{id:"54021",title:"Prof.",name:"Ilze",middleName:null,surname:"Strumfa",slug:"ilze-strumfa",fullName:"Ilze Strumfa"},{id:"159998",title:"Dr.",name:"Arnis",middleName:null,surname:"Abolins",slug:"arnis-abolins",fullName:"Arnis Abolins"},{id:"160000",title:"Prof.",name:"Janis",middleName:null,surname:"Gardovskis",slug:"janis-gardovskis",fullName:"Janis Gardovskis"},{id:"174929",title:"Dr.",name:"Andrejs",middleName:null,surname:"Vanags",slug:"andrejs-vanags",fullName:"Andrejs Vanags"},{id:"202252",title:"Dr.",name:"Arvids",middleName:null,surname:"Jakovlevs",slug:"arvids-jakovlevs",fullName:"Arvids Jakovlevs"},{id:"202253",title:"Dr.",name:"Dainis",middleName:null,surname:"Balodis",slug:"dainis-balodis",fullName:"Dainis Balodis"},{id:"203012",title:"Dr.",name:"Ilze",middleName:null,surname:"Fridrihsone",slug:"ilze-fridrihsone",fullName:"Ilze Fridrihsone"},{id:"205692",title:"MSc.",name:"Boriss",middleName:null,surname:"Strumfs",slug:"boriss-strumfs",fullName:"Boriss Strumfs"}]},{id:"58184",title:"Benign Tumors of Temporomandibular Joint",slug:"benign-tumors-of-temporomandibular-joint",totalDownloads:1235,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"temporomandibular-joint-pathology-current-approaches-and-understanding",title:"Temporomandibular Joint Pathology",fullTitle:"Temporomandibular Joint Pathology - Current Approaches and Understanding"},signatures:"Mehmet Emre Yurttutan, Ayşegül Tüzüner Öncül and Hakan Alpay\nKarasu",authors:[{id:"178706",title:"Dr.",name:"Aysegul",middleName:null,surname:"Tuzuner Oncul",slug:"aysegul-tuzuner-oncul",fullName:"Aysegul Tuzuner Oncul"},{id:"213436",title:"Dr.",name:"Mehmet Emre",middleName:null,surname:"Yurttutan",slug:"mehmet-emre-yurttutan",fullName:"Mehmet Emre Yurttutan"},{id:"213439",title:"Prof.",name:"Hakan Alpay",middleName:null,surname:"Karasu",slug:"hakan-alpay-karasu",fullName:"Hakan Alpay Karasu"}]},{id:"55576",title:"The Roles of Indoxyl Sulphate and p-Cresyl Sulphate in Patients with Chronic Kidney Disease: A Review of Therapeutic Options",slug:"the-roles-of-indoxyl-sulphate-and-p-cresyl-sulphate-in-patients-with-chronic-kidney-disease-a-review",totalDownloads:791,totalCrossrefCites:1,totalDimensionsCites:3,book:{slug:"chronic-kidney-disease-from-pathophysiology-to-clinical-improvements",title:"Chronic Kidney Disease",fullTitle:"Chronic Kidney Disease - from Pathophysiology to Clinical Improvements"},signatures:"Melissa Nataatmadja, Yeoungjee Cho, Katrina Campbell and David\nW. Johnson",authors:[{id:"50425",title:"Prof.",name:"David",middleName:null,surname:"Johnson",slug:"david-johnson",fullName:"David Johnson"},{id:"183338",title:"Dr.",name:"Yeoungjee",middleName:null,surname:"Cho",slug:"yeoungjee-cho",fullName:"Yeoungjee Cho"},{id:"205845",title:"Dr.",name:"Melissa",middleName:null,surname:"Nataatmadja",slug:"melissa-nataatmadja",fullName:"Melissa Nataatmadja"},{id:"205846",title:"Dr.",name:"Katrina",middleName:null,surname:"Campbell",slug:"katrina-campbell",fullName:"Katrina Campbell"}]},{id:"57259",title:"Subjective Wellbeing Assessment in People with Chronic Kidney Disease Undergoing Hemodialysis",slug:"subjective-wellbeing-assessment-in-people-with-chronic-kidney-disease-undergoing-hemodialysis",totalDownloads:1514,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"chronic-kidney-disease-from-pathophysiology-to-clinical-improvements",title:"Chronic Kidney Disease",fullTitle:"Chronic Kidney Disease - from Pathophysiology to Clinical Improvements"},signatures:"Luís Manuel Mota de Sousa, Ana Vanessa Antunes, Cristina Rosa\nSoares Lavareda Baixinho, Sandy Silva Pedro Severino, Cristina\nMaria Alves Marques-Vieira and Helena Maria Guerreiro José",authors:[{id:"220206",title:"Ph.D.",name:"Luís",middleName:"Manuel Mota",surname:"Sousa",slug:"luis-sousa",fullName:"Luís Sousa"},{id:"220843",title:"Prof.",name:"Ana Vanessa",middleName:null,surname:"Antunes",slug:"ana-vanessa-antunes",fullName:"Ana Vanessa Antunes"},{id:"220844",title:"Dr.",name:"Sandy",middleName:"S P",surname:"Severino",slug:"sandy-severino",fullName:"Sandy Severino"},{id:"220847",title:"Prof.",name:"Cristina M. A.",middleName:null,surname:"Marques-Vieira",slug:"cristina-m.-a.-marques-vieira",fullName:"Cristina M. A. Marques-Vieira"},{id:"220848",title:"Prof.",name:"Cristina R. S. L.",middleName:null,surname:"Baixinho",slug:"cristina-r.-s.-l.-baixinho",fullName:"Cristina R. S. L. Baixinho"},{id:"220849",title:"Prof.",name:"Helena M. G.",middleName:null,surname:"José",slug:"helena-m.-g.-jose",fullName:"Helena M. G. José"}]}],onlineFirstChaptersFilter:{topicSlug:"medicine-pathology",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/191239/c-e-miller",hash:"",query:{},params:{id:"191239",slug:"c-e-miller"},fullPath:"/profiles/191239/c-e-miller",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()